<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Methotrexate for treating rheumatoid arthritis - Lopez‐Olivo, MA - 2014 | Cochrane Library</title> <meta content="Methotrexate for treating rheumatoid arthritis - Lopez‐Olivo, MA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000957.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Methotrexate for treating rheumatoid arthritis - Lopez‐Olivo, MA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000957.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000957.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Methotrexate for treating rheumatoid arthritis" name="citation_title"/> <meta content="Maria Angeles Lopez‐Olivo" name="citation_author"/> <meta content="The University of Texas, M.D. Anderson Cancer Center" name="citation_author_institution"/> <meta content="Harish R Siddhanamatha" name="citation_author"/> <meta content="The University of Texas, M.D. Anderson Cancer Center" name="citation_author_institution"/> <meta content="Beverley Shea" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Peter Tugwell" name="citation_author"/> <meta content="Faculty of Medicine, University of Ottawa" name="citation_author_institution"/> <meta content="George A Wells" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Maria E Suarez‐Almazor" name="citation_author"/> <meta content="The University of Texas, M.D. Anderson Cancer Center" name="citation_author_institution"/> <meta content="msalmazor@mdanderson.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD000957.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000957.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000957.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000957.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antirheumatic Agents [adverse effects, *therapeutic use]; Arthritis, Rheumatoid [*drug therapy]; Folic Acid Antagonists [adverse effects, *therapeutic use]; Medication Adherence [statistics &amp; numerical data]; Methotrexate [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000957.pub2&amp;doi=10.1002/14651858.CD000957.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000957\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000957\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000957.pub2",title:"Methotrexate for treating rheumatoid arthritis",firstPublishedDate:"Jun 10, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000957.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000957.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000957.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000957.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000957.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000957.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000957.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000957.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000957.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000957.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10195 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000957.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0070"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-sec-0064"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/appendices#CD000957-sec-0075"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/table_n/CD000957StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/table_n/CD000957StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Methotrexate for treating rheumatoid arthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0002">Maria Angeles Lopez‐Olivo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0003">Harish R Siddhanamatha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0004">Beverley Shea</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0005">Peter Tugwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0006">George A Wells</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information#CD000957-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Maria E Suarez‐Almazor</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information/en#CD000957-sec-0084">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000957.pub2">https://doi.org/10.1002/14651858.CD000957.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000957-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000957-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000957-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000957-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000957-abs-0001" lang="en"> <section id="CD000957-sec-0001"> <h3 class="title" id="CD000957-sec-0001">Background</h3> <p>Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins by binding to dihydrofolate reductase. Currently, methotrexate is among the most commonly used drugs for the treatment of rheumatoid arthritis (RA). This is an update of the previous Cochrane systematic review published in 1997. </p> </section> <section id="CD000957-sec-0002"> <h3 class="title" id="CD000957-sec-0002">Objectives</h3> <p>To evaluate short term benefits and harms of methotrexate for treating RA compared to placebo. </p> </section> <section id="CD000957-sec-0003"> <h3 class="title" id="CD000957-sec-0003">Search methods</h3> <p>The Cochrane Musculoskeletal Group Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE were searched from 1966 to 1997 and then updated to November 2013. The search was complemented with a bibliography search of the reference lists of trials retrieved from the electronic search. </p> </section> <section id="CD000957-sec-0004"> <h3 class="title" id="CD000957-sec-0004">Selection criteria</h3> <p>Randomized controlled trials and controlled clinical trials comparing methotrexate (MTX) monotherapy against placebo alone in people with RA. Any trial duration and MTX doses were included. </p> </section> <section id="CD000957-sec-0005"> <h3 class="title" id="CD000957-sec-0005">Data collection and analysis</h3> <p>Two review authors independently determined which studies were eligible for inclusion, extracted data and assessed risk of bias. Outcomes were pooled using mean differences (MDs) for continuous variables or standardized mean differences (SMDs) when different scales were used to measure the same outcome. Pooled risk ratio (RR) was used for dichotomous variables. Fixed‐effect models were used throughout, although random‐effects models were used for outcomes showing heterogeneity. </p> </section> <section id="CD000957-sec-0006"> <h3 class="title" id="CD000957-sec-0006">Main results</h3> <p>Five trials with 300 patients were included in the original version of the review. An additional two trials with 432 patients were added to the 2013 update of the review for a total of 732 participants. The trials were generally of unclear to low risk of bias with a follow‐up duration ranging from 12 to 52 weeks. All trials included patients who have failed prior treatment (for example, gold therapy, D‐penicillamine, azathioprine or anti‐malarials); mean disease duration that ranged between 1 and 14 years with six trials reporting more than 4 years; and weekly doses that ranged between 5 mg and 25 mg. </p> <p><b>Benefits</b> </p> <p>Statistically significant and clinically important differences were observed for most efficacy outcomes. MTX monotherapy showed a clinically important and statistically significant improvement in the American College of Rheumatology (ACR) 50 response rate when compared with placebo at 52 weeks (RR 3.0, 95% confidence interval (CI) 1.5 to 6.0; number needed to treat (NNT) 7, 95% CI 4 to 22). Fifteen more patients out of 100 had a major improvement in the ACR 50 outcome compared to placebo (absolute treatment benefit (ATB) 15%, 95% CI 8% to 23%). </p> <p>Statistically significant improvement in physical function (scale of 0 to 3) was also observed in patients receiving MTX alone compared with placebo at 12 to 52 weeks (MD ‐0.27, 95% CI ‐0.39 to ‐0.16; odds ratio (OR) 2.8, 95% CI 0.23 to 32.2; NNT 4, 95% CI 3 to 7). Nine more patients out of 100 improved in physical function compared to placebo (ATB ‐9%, 95% CI ‐13% to ‐5.3%). Similarly, the proportion of patients who improved at least 20% on the Short Form‐36 (SF‐36) physical component was higher in the MTX‐treated group compared with placebo at 52 weeks (RR 1.5, 95% CI 1.0 to 2.1; NNT 9, 95% CI 4 to 539). Twelve more patients out of 100 showed an improvement of at least 20% in the physical component of the quality of life measure compared to placebo (ATB 12%, 95% CI 1% to 24%). No clinically important or statistically significant differences were observed in the SF‐36 mental component. </p> <p>Although no statistically significant differences were observed in radiographic scores (that is, Total Sharp score, erosion score, joint space narrowing), radiographic progression rates (measured by an increase in erosion scores of more than 3 units on a scale ranging from 0 to 448) were statistically significantly lower for patients in the MTX group compared with placebo‐treated patients (RR 0.31, 95% CI 0.11 to 0.86; NNT 13, 95% CI 10 to 60). Eight more patients out of 100 showed less damage to joints measured by an increase in erosion scores compared to placebo (ATB ‐8%, 95% CI ‐16% to ‐1%). In the one study measuring remission, no participants in either group met the remission criteria. These are defined by at least five of (≥ 2 months): morning stiffness of &lt; 15 minutes, no fatigue, no joint pain by history, no joint tenderness, no joint swelling, and Westergren erythrocyte sedimentation rate (ESR) of &lt; 20 mm/hr in men and &lt; 30 mm/hr in women. </p> <p><b>Harms</b> </p> <p>Patients in the MTX monotherapy group were twice as likely to discontinue from the study due to adverse events compared to patients in the placebo group, at 12 to 52 weeks (16% versus 8%; RR 2.1, 95% CI 1.3 to 3.3; NNT 13, 95% CI 6 to 44). Compared to placebo, nine more people out of 100 who took MTX withdrew from the studies because of side effects (ATB 9%, 95% CI 3% to 14%). Total adverse event rates at 12 weeks were higher in the MTX monotherapy group compared to the placebo group (45% versus 15%; RR 3.0, 95% CI 1.4 to 6.4; NNT 4, 95% CI 2 to 17). Thirty more people out of 100 who took MTX compared to those who took placebo experienced any type of side effect (common or rare) (ATB 30, 95% CI 13% to 47%). No statistically significant differences were observed in the total number of serious adverse events between the MTX group and the placebo group at 27 to 52 weeks. Three people out of 100 who took MTX alone experienced rare but serious side effects compared to 2 people out of 100 who took a placebo (3% versus 2%, respectively). </p> </section> <section id="CD000957-sec-0007"> <h3 class="title" id="CD000957-sec-0007">Authors' conclusions</h3> <p>Based on mainly moderate to high quality evidence, methotrexate (weekly doses ranging between 5 mg and 25 mg) showed a substantial clinical and statistically significant benefit compared to placebo in the short term treatment (12 to 52 weeks) of people with RA, although its use was associated with a 16% discontinuation rate due to adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000957-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000957-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000957-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000957-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000957-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000957-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000957-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000957-abs-0003" lang="en"> <h3>Methotrexate for treating rheumatoid arthritis</h3> <p>We looked at studies until November 2013 on the effect of receiving methotrexate alone compared to placebo (no treatment) over 12 to 52 weeks in 732 people with rheumatoid arthritis. </p> <p><b>Key findings</b> </p> <p>In the short term treatment of people with rheumatoid arthritis, methotrexate:</p> <p>‐ improves pain, function and other symptoms;</p> <p>‐ probably reduces joint damage as seen on the x‐ray.</p> <p>Precise information about side effects and complications was not always available. Common side effects may include nausea, vomiting, diarrhoea, loss of appetite, stomach pain, and sores on lips, mouth or throat. Rare complications may include birth defects, kidney, lung and liver problems. </p> <p><b>What is rheumatoid arthritis and what is methotrexate?</b> </p> <p>When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints making your joints swollen, stiff and painful.<br/> Treatments aim to decrease symptoms and improve your ability to move. </p> <p>Methotrexate is one of a group of medications called disease‐modifying antirheumatic drugs (DMARDs) and it is the most common treatment for rheumatoid arthritis. Methotrexate helps prevent further permanent damage that can happen if rheumatoid arthritis is not treated. </p> <p><b>What happens to people with rheumatoid arthritis who take methotrexate alone?</b> </p> <p><b>ACR 50 (number of tender or swollen joints and other outcomes such as pain and disability)</b> <br/> ‐ 15 more people out of 100 experienced major improvement in the symptoms of their rheumatoid arthritis after 12 months with methotrexate when compared to placebo (15% absolute improvement).<br/> ‐ 23 people out of 100 who took methotrexate alone experienced major improvement.<br/> ‐ 8 people out of 100 who took a placebo experienced major improvement. </p> <p><b>Remission or absence of active disease</b> </p> <p>In people who took either placebo or methotrexate, none had absence of active disease.</p> <p><b>Disability (lower scores mean lower disability)</b> </p> <p>‐ People who took methotrexate rated their disability to be 0.27 points lower on a scale of 0 to 3 after 3 to 12 months with methotrexate when compared to placebo (9% absolute improvement).<br/> ‐ People who took methotrexate rated their disability to be between 0.39 and 1.04.<br/> ‐ People who took placebo rated their disability to be between 0.53 and 1.34. </p> <p><b>Quality of life ‐ physical component (ability to perform physical activities at least 20% better)</b> </p> <p>‐ 12 more people out of 100 perceived their ability to perform physical activities at least 20% better after 12 months with methotrexate alone compared to placebo (12% absolute improvement).<br/> ‐ 39 people out of 100 who took methotrexate alone perceived their ability to perform physical activities at least 20% better.<br/> ‐ 27 people out of 100 who took a placebo perceived their ability to perform physical activities at least 20% better. </p> <p><b>Quality of life ‐ mental component</b> </p> <p>‐ 5 more people out of 100 perceived their mental well‐being better after 12 months with methotrexate alone compared to placebo (5% absolute improvement).<br/> ‐ 26 people out of 100 who took methotrexate alone perceived their mental well‐being better.<br/> ‐ 21 people out of 100 who took a placebo perceived their mental well‐being better. </p> <p><b>X‐rays of the joints</b> <br/> ‐ 8 more people out of 100 had less x‐ray damage to joints measured by increase in erosion scores of more than 3 units on a scale ranging from 0 to 448 in people who took methotrexate compared to placebo after 12 months (8% absolute reduction).<br/> ‐ 4 people out of 100 who took methotrexate alone had increased damage to joints measured by x‐ray.<br/> ‐12 people out of 100 who took a placebo had increase damage to joints measured by x‐ray. </p> <p><b>Discontinuations due to adverse events (side effects and complications)</b> <br/> ‐ 9 more people out of 100 discontinued methotrexate due to adverse events after 3 to 12 months compared to placebo (9% absolute withdrawals).<br/> ‐ 16 people out of 100 who took methotrexate alone discontinued methotrexate due to adverse events.<br/> ‐ 8 people out of 100 who took a placebo discontinued placebo due to adverse events. </p> <p><b>Serious adverse events</b> <br/> ‐ 1 more person out of 100 experienced serious side effects after 3 to 12 months with methotrexate alone compared to placebo (1% absolute harm).<br/> ‐ 3 people out of 100 who took methotrexate alone experienced serious side effects.<br/> ‐ 2 people out of 100 who took a placebo experienced serious side effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000957-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000957-sec-0070"></div> <h3 class="title" id="CD000957-sec-0071">Implications for practice</h3> <section id="CD000957-sec-0071"> <p>Based on mainly moderate to high quality evidence, methotrexate has a substantial clinical and statistically significant benefit compared to placebo in the short term treatment of people with RA. However, its use was associated with a 16% discontinuation rate due to adverse events. </p> </section> <h3 class="title" id="CD000957-sec-0072">Implications for research</h3> <section id="CD000957-sec-0072"> <p>Although, the long term effectiveness or safety profile of methotrexate cannot be established with this review, time trend analyses indicate that methotrexate monotherapy has a two‐year drug survival (<a href="./references#CD000957-bbs2-0014" title="AgaAB , LieE , UhligT , OlsenIC , WierødA , KalstadS , et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR‐DMARD study 2000‐2010. Annals of the Rheumatic Diseases2013;Nov 27:epub. [doi: 10.1136/annrheumdis‐2013‐204020; PUBMED: 24285493] ">Aga 2013</a>). Methotrexate continues to be the most prescribed drug for the treatment of RA. This review provides the centrepiece evidence to further compare the effects of methotrexate as the standard of care to other disease‐modifying antirheumatic drugs (traditional or biologic), monotherapy or combinations in network meta‐analyses. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000957-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000957-sec-0015"></div> <div class="table" id="CD000957-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate for rheumatoid arthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Methotrexate for rheumatoid arthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with rheumatoid arthritis<br/> <b>Settings:</b> rheumatology clinics<br/> <b>Intervention:</b> methotrexate (weekly doses ranging between 5 mg and 25 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="2" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ACR 50</b> <br/> American College of Rheumatology improvement criteria<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> <br/> (12 to 46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.0</b> <br/> (1.5 to 6.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute treatment benefit 15% (95% CI 8% to 23%); Relative percent change 203% (95% CI 53% to 498%); NNTB 7 (95% CI 4 to 22); <a href="./references#CD000957-fig-0005" title="">Analysis 1.2</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Remission</b><sup>3</sup> </p> <p>Follow‐up: 18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant. No patients in either group met the remission criteria</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Functional Status</b> <br/> Health Assessment Questionnaire Disability Index . Scale from: 0 to 3<br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean functional status ranged across control groups from<br/> <b>0.53‐1.34 units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean functional status in the intervention groups was<br/> <b>0.27 lower</b> <br/> (0.39 to 0.16 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit ‐9% (95% CI ‐13% to ‐5.3%); Relative percent change 20% (95% CI 29% to 12%); <a href="./references#CD000957-fig-0023" title="">Analysis 2.1</a>The reported final mean scores in the methotrexate group was 1.0 and in the placebo group 1.3. NNTB 4 (95% CI 3 to 7)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Health‐Related Quality of Life</b> </p> <p>at least 20% improvement<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SF‐36</b> Physical Component </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 per 100</b> <br/> (27 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> <br/> (1 to 2.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit 12% (95% CI 1% to 24%); Relative percent change 45% (95% CI 0% to 112%); NNTB 9 (95% CI 4 to 539); <a href="./references#CD000957-fig-0029" title="">Analysis 2.7</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SF‐36</b> Mental Component </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 100</b> </p> <p>(16 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.3</b> <br/> (0.79 to 2.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant; Absolute treatment benefit 5% (95% CI ‐5% to 16%); Relative percent change 25% (95% CI ‐21% to 98%); <a href="./references#CD000957-fig-0030" title="">Analysis 2.8</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Radiographic Progression</b> <br/> Increase in erosion scores of &gt; 3 units<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (1 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.31</b> <br/> (0.11 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit ‐8% (95% CI ‐16% to ‐1%); Relative percent change ‐69% (95% CI ‐89% to ‐14%); NNTB 13 (95% CI 10 to 60); <a href="./references#CD000957-fig-0038" title="">Analysis 3.1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Discontinuations</b> <br/> <b>due to adverse events</b> </p> <p>Follow‐up: 12‐52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 per 100</b> <br/> (10 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.1</b> <br/> (1.3 to 3.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>613<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit 9% (95% CI 3% to 14%); Relative percent change 106% (95% CI 30% to 225%); NNTH 13 (95% CI 6 to 44); <a href="./references#CD000957-fig-0045" title="">Analysis 4.3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious Adverse Events</b> <br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.4</b> <br/> (0.36 to 5.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant; Absolute treatment benefit 1% (95% CI ‐3% to 4%); Relative percent change 44% (95% CI ‐64% to 474%); <a href="./references#CD000957-fig-0061" title="">Analysis 5.2</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Only one study reported this outcome. Probability of publication bias: published evidence is limited to a small number of trials, all of which are showing benefits of the studied intervention. </p> <p><sup>2</sup>Limitations in the design and implementation of available studies suggesting high likelihood of bias. Analysis was performed in the completers population and the discontinuation rate was higher than 20%<br/> <sup>3</sup><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> categorized patients to be in therapeutic remission if they had at least 5 of (≥2 months): morning stiffness of &lt;15 minutes, no fatigue, no joint pain by history, no joint tenderness, no joint swelling, and Westergren ESR of &lt;20 mm/hr in men and &lt;30 mm/hr in women. </p> <p><sup>4</sup><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> used as the control group baseline mean and control group standard deviation for calculations. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000957-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000957-sec-0016"></div> <section id="CD000957-sec-0017"> <h3 class="title" id="CD000957-sec-0017">Description of the condition</h3> <p>Rheumatoid arthritis (RA) is a chronic, systemic inflammatory condition of unknown cause. Clinical presentation can include synovial proliferation, symmetric erosive arthritis, and systemic involvement. </p> </section> <section id="CD000957-sec-0018"> <h3 class="title" id="CD000957-sec-0018">Description of the intervention</h3> <p>Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins by binding to dihydrofolate reductase. </p> </section> <section id="CD000957-sec-0019"> <h3 class="title" id="CD000957-sec-0019">How the intervention might work</h3> <p>The potential benefits of methotrexate for the treatment of RA were originally suggested by <a href="./references#CD000957-bbs2-0022" title="GubnerR , AugustS , GinsburgV . Therapeutic suppression of tissue reactivity.II. Effects of aminopterin in rheumatoid arthritis and psoriasis. American Journal of Medicine1951;221(2):176‐82. ">Gubner 1951</a> in a case series study of six patients with RA. Subsequent open trials supported the efficacy of the drug (<a href="./references#CD000957-bbs2-0021" title="GroffBD , ShenbergerKN , WilkeWS , TaylorTH . Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature. Seminars in Arthritis and Rheumatism1983;12:333‐47. ">Groff 1983</a>; <a href="./references#CD000957-bbs2-0034" title="SteinssonK , WeinsteinA , KornJ , AbelesM . Low dose methotrexate in rheumatoid arthritis. Journal of Rheumatology1982;9:860‐6. ">Steinsson 1982</a>; <a href="./references#CD000957-bbs2-0039" title="WillkensRF , WatsonMA , PaxsonCS . Low dose pulse methotrexate therapy in rheumatoid arthritis. Journal of Rheumatology1980;7:501‐5. ">Willkens 1980</a>). The first controlled trials of methotrexate against placebo in people with RA were reported in the 1980s. Currently, methotrexate is among the most commonly used drugs for the treatment of RA. </p> </section> <section id="CD000957-sec-0020"> <h3 class="title" id="CD000957-sec-0020">Why it is important to do this review</h3> <p>This systematic review synthesizes and updates the evidence of a previous published Cochrane review reporting the benefits and harms of methotrexate monotherapy compared to placebo. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000957-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000957-sec-0021"></div> <p>To evaluate the short term benefits and harms of methotrexate for the treatment of RA compared to placebo. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000957-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000957-sec-0022"></div> <section id="CD000957-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000957-sec-0024"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) and clinical controlled trials (CCTs) comparing methotrexate with placebo for a minimum duration of 12 weeks. Twelve weeks is thought to be the minimum treatment duration required to adequately assess the efficacy of methotrexate. We included studies reported as full‐text, published as abstract only, and unpublished data. There was no language restriction. </p> </section> <section id="CD000957-sec-0025"> <h4 class="title">Types of participants</h4> <p>People with a diagnosis of RA that was severe and of long duration, who had a high prevalence of positive rheumatoid factor (RF), and had previously failed other second line disease‐modifying antirheumatic drug (DMARD) therapy. </p> </section> <section id="CD000957-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing methotrexate (oral or parenteral) at a dose level of at least 5 mg per week with placebo. Only trials with a treatment duration of at least 12 weeks in a double‐blind phase were considered for inclusion. </p> </section> <section id="CD000957-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD000957-sec-0028"> <h5 class="title">Major outcomes</h5> <p>1. All the outcome measures in <a href="./references#CD000957-bbs2-0028" title="OMERACT . Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology1993;20:526‐91. ">OMERACT 1993</a> were included for potential analysis. OMERACT measures for efficacy include:<br/> a) number of tender joints per patient; b) number of swollen joints per patient; c) pain (Visual Analogue Scale or VAS); d) physician global assessment; e) patient global assessment; f) Functional status (measured by a validated scale such as the Health Assessment Questionnaire (HAQ)); g) acute phase reactants, including erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP). </p> <p>2. American College of Rheumatology (ACR) core set: ACR 20, 50, or 70 responses (<a href="./references#CD000957-bbs2-0019" title="FelsonDT , AndersonJJ , BoersM , et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism1995;38:727‐35. ">Felson 1995</a>). </p> <p>3. Remission measured by disease activity (<a href="./references#CD000957-bbs2-0036" title="van derHeijdeD , KlareskogL , BoersM , LandeweR , CodreanuC , BolosiuHD . Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of the Rheumatic Diseases2005;64:1582–7. ">van der Heijde 2005</a>) using the disease activity score (DAS) &lt; 1.6 or DAS28 &lt; 2.6, or as specified by the authors. </p> <p>4. Radiological damage (joint damage shown on x‐ray).</p> <p>5. Discontinuations. These were analysed as discontinuations because of adverse events, lack of efficacy, and due to system‐specific adverse reactions (e.g. gastrointestinal, renal, etc). </p> <p>6. Adverse events. Number of patients who experienced serious, total, or individual adverse events. </p> </section> <section id="CD000957-sec-0029"> <h5 class="title">Minor outcomes</h5> <p>Health‐related quality of life measured by validated scales including the Medical Outcomes Study Short‐Form 36 (SF‐36) and activities of daily living (ADL). </p> </section> </section> </section> <section id="CD000957-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000957-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Musculoskeletal Group register, Cochrane Controlled Trials Register (CCTR), MEDLINE (1966 to July 1997) and EMBASE (1988 to July 1997) were searched using the strategy developed by <a href="./references#CD000957-bbs2-0016" title="DickersinK , SchererR , LefebvreC . Identifying relevant studies for systematic reviews. BMJ1994;309:1286‐91. ">Dickersin 1994</a>. A further search was performed from 1997 to November 2013 in MEDLINE (<a href="./appendices#CD000957-sec-0076">Appendix 1</a>), CENTRAL in <i>The Cochrane Library</i> (<a href="./appendices#CD000957-sec-0077">Appendix 2</a>), EMBASE (<a href="./appendices#CD000957-sec-0078">Appendix 3</a>), Web of Science (<a href="./appendices#CD000957-sec-0079">Appendix 4</a>), and ClinicalTrials.gov (<a href="./appendices#CD000957-sec-0080">Appendix 5</a>). The search was not limited by language, year of publication or type of publication. The MEDLINE search strategy that was used is located in <a href="./appendices#CD000957-sec-0076">Appendix 1</a>. This strategy was modified for the other databases. </p> </section> <section id="CD000957-sec-0032"> <h4 class="title">Searching other resources</h4> <p>Reference lists of all the trials selected through the electronic searches were manually searched to identify additional trials. Key experts in the area were contacted for further published and unpublished articles. The ClinicalTrials.gov (www.ClinicalTrials.gov) website and the World Health Organization (WHO) International Clinical Trials Registry Platform trials portal (www.who.int/ictrp/en/) were also searched to identify any ongoing trials, in November 2013. </p> <p>For safety assessments, we searched the websites of the regulatory agencies (US Food and Drug Administration‐MedWatch (<a href="http://www.fda.gov/Safety/MedWatch/default.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/default.htm</a>), European Medicines Evaluation Agency (<a href="http://www.ema.europa.eu/" target="_blank">http://www.ema.europa.eu</a>), Australian Adverse Drug Reactions Bulletin (<a href="http://www.tga.gov.au/safety/ews-monitoring.htm" target="_blank">http://www.tga.gov.au/safety/ews‐monitoring.htm</a>), and UK Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance and drug safety updates (<a href="http://www.mhra.gov.uk/Safetyinformation/index.htm" target="_blank">http://www.mhra.gov.uk/Safetyinformation/index.htm</a>) using the keyword ‘methotrexate’ on 19 March 2014. </p> </section> </section> <section id="CD000957-sec-0033"> <h3 class="title" id="CD000957-sec-0033">Data collection and analysis</h3> <section id="CD000957-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MLO, HRS) independently screened the titles and abstracts of all the potential studies identified as a result of the search for inclusion and coded them as 'retrieve' (eligible or potentially eligible or unclear) or 'do not retrieve'. Next, two review authors (MLO, HRS) independently screened the full‐texts and identified studies for inclusion, and recorded reasons for exclusion of the ineligible studies. Disagreement were resolved through discussion or, when required, by a third review author (MSA). We identified and excluded duplicates, and collated multiple reports of the same study. </p> </section> <section id="CD000957-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which was piloted using one study in the review. Two review authors (MLO, HRS) extracted the study characteristics and outcome measures of efficacy and toxicity from the included studies. </p> </section> <section id="CD000957-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MLO, HRS) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000957-bbs2-0023" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration2011;Available from www.cochrane‐handbook.org.:Accessed on: 09/16/2013. ">Higgins 2011</a>). Disagreements were resolved by consensus. We assessed the risk of bias according to several domains including: a) random sequence generation, b) allocation concealment, c) blinding of participants and personnel, d) blinding of outcome assessment, e) incomplete outcome data, f) selective outcome reporting, g) other bias (that is, baseline imbalance). We graded each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. Figures were generated to provide summary assessments of the risk of bias. </p> </section> <section id="CD000957-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous data were analysed as risk ratios (RR) and 95% confidence intervals (CI) were also estimated. Continuous data were pooled as mean differences (MD) with corresponding 95% CI or standardized mean differences (SMD) in the case of joint scores, pain, global and functional assessments. This was necessary because of the variation in the outcome measures included in each study (for example, different number of swollen joints counted). Trial results were entered into RevMan using the same direction in order to enable the pooling of results, with the lower values indicating better responses. Negative values in SMD indicated a benefit of the active drug over placebo. The SMD was back‐translated to a typical scale (for example, 0 to 10 for pain) by multiplying the SMD by a typical among‐person standard deviation (for example, the standard deviation of the control group at baseline from the most representative trial) (<a href="./references#CD000957-bbs2-0023" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration2011;Available from www.cochrane‐handbook.org.:Accessed on: 09/16/2013. ">Higgins 2011</a>). </p> </section> <section id="CD000957-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to include cross‐over randomised trials, but only if data from the first period were reported<i>.</i> When multiple methotrexate doses were evaluated in a single trial, we included only the most relevant (close to clinical practice) dosage. </p> </section> <section id="CD000957-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Authors from two trials were contacted to obtain missing numerical outcome data, but no response was obtained. For continuous outcomes, we calculated the effect estimate based on the number of patients analysed at the final visit. If the number of patients analysed was not presented, the number reported at baseline was used. When only median and interquartile ranges were reported, the median was used as the mean and one half of the difference between the first and third quartile range was used as the standard deviation. When the end‐of‐trial standard deviation was not reported we used the baseline standard deviation for the pooled analysis. In our experience, the baseline standard deviation of RA outcome measures is often very close to the end‐of‐trial standard deviation, perhaps slightly larger. This resultant bias would therefore result in decreased weighting of the studies and is preferable to completely excluding them. If no standard deviation was provided at baseline, missing standard deviations were computed from other statistics such as standard errors or imputed from other studies in the meta‐analysis. When numerical data were only reported graphically, the value was extracted from the graph. </p> </section> <section id="CD000957-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>The heterogeneity of the trials for each pooled analysis was estimated using the Chi<sup>2</sup> test and I<sup>2</sup> statistic. For the Chi<sup>2</sup> test, a P value ≤ 0.10 indicated evidence of statistical heterogeneity. An I<sup>2</sup> value of 0% to 40% might 'not be important'; 30% to 60% may represent 'moderate' heterogeneity; 50% to 90% may represent 'substantial' heterogeneity; and 75% to 100% represents 'considerable' heterogeneity (<a href="./references#CD000957-bbs2-0023" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration2011;Available from www.cochrane‐handbook.org.:Accessed on: 09/16/2013. ">Higgins 2011</a>). </p> </section> <section id="CD000957-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>A funnel plot was not planned a priori. In addition, this could not be created for the updated version of the review due to the limited number of studies that were included. </p> </section> <section id="CD000957-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Fixed‐effect models were used throughout. Random‐effects models were used for outcomes showing statistically significant heterogeneity. </p> <section id="CD000957-sec-0043"> <h5 class="title">Summary of findings table</h5> <p>A 'Summary of findings' table was created using the following outcomes: 1) ACR 50 response, 2) disease remission, 3) functional status, 4) health‐related quality of life, 5) radiographic progression, 6) discontinuations due to adverse events, 7) serious adverse events. </p> <p>Two people (MLO, HRS) independently assessed the quality of the evidence. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies which contributed data to the meta‐analyses for the prespecified outcomes. In the comments column of the summary of findings table we provided the absolute per cent difference, the relative per cent change from baseline, and the number needed‐to‐treat (NNT). </p> <p>For dichotomous outcomes, the absolute risk difference was calculated using the risk difference statistic in RevMan and the result expressed as a percentage. For continuous outcomes, the absolute benefit was calculated as the improvement in the intervention group minus the improvement in the control group, in the original units. </p> <p>The relative per cent change for dichotomous data was calculated as the risk ratio ‐ 1 and expressed as a percentage. For continuous outcomes, the relative difference in the change from baseline was calculated as the absolute benefit divided by the baseline mean of the control group. </p> <p>The number needed to treat (NNT) was provided only when the outcome showed a statistically significant difference. For dichotomous outcomes, the NNT was calculated from the control group event rate and the relative risk using the Visual Rx NNT calculator (<a href="./references#CD000957-bbs2-0015" title="Visual Rx [Computer program]. Version 3.. Dr. Christopher Cates EBM web site2008:URL: http://www.nntonline.net. ">Cates 2008</a>). The NNT for the functional status was calculated using the Wells calculator (available at the CMSG Editorial office). </p> </section> </section> <section id="CD000957-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The results on efficacy were analysed for all the study endpoints (12, 18, 27, and 52 weeks). We evaluated subgroup interactions and compared the magnitude of the effects between the subgroups by assessing the overlap of the confidence intervals of the summary measures estimated. Non‐overlap of the confidence intervals indicated statistical significance. </p> </section> <section id="CD000957-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>For the cross‐over trials where data from the first period was not provided for both arms, we explored the impact of including the studies in the overall assessment of results by a sensitivity analysis<b>.</b> For dichotomous outcomes (for example, number of withdrawals due to adverse events), we also compared the magnitude of the effects when using the intention to treat population versus completers as the denominator. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000957-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000957-sec-0046"></div> <section id="CD000957-sec-0047"> <h3 class="title">Description of studies</h3> <p>The methods of the included studies are summarised in the <a href="./references#CD000957-sec-0090" title="">Characteristics of included studies</a> tables. </p> <section id="CD000957-sec-0048"> <h4 class="title">Results of the search</h4> <p>The search strategy for the original review was run from inception to 1997. From 11 potentially eligible articles, only 5 trials (8 publications) met the inclusion criteria (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). For the update, a search strategy was run from 1997 to November 2013. <a href="#CD000957-fig-0001">Figure 1</a> shows a flow diagram of the disposition of the studies. For the update, there were 6859 unique citations retrieved from the electronic databases. After screening the titles and abstracts, we found 3099 relevant citations. Of these, 3090 were excluded (combined methotrexate or no placebo group). We retrieved the full‐texts of 9 potentially eligible articles, but a further 3 were excluded (combined placebo group). Only two new trials (six publications) met the inclusion criteria (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). </p> <div class="figure" id="CD000957-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of the included studies.*Additional data were unavailable since at the time of the publication this information was not required to be reported." data-id="CD000957-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of the included studies.</p> <p>*Additional data were unavailable since at the time of the publication this information was not required to be reported. </p> </div> </div> </div> </section> <section id="CD000957-sec-0049"> <h4 class="title">Included studies</h4> <p>The summary of the characteristics of included studies and participants are shown in <a href="#CD000957-tbl-0002">Table 1</a> and <a href="#CD000957-tbl-0003">Table 2</a>. </p> <div class="table" id="CD000957-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study, year</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country (# sites)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up duration</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Methotrexate dose, frequency and route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Methotrexate</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>15<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States (2 centres)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐25 mg IM weekly doses<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grant from Veterans administration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/m<sup>2c</sup>, 10 mg/m<sup>2</sup> orally, weekly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRC Grant RR59 and Lederle laboratories</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 mg‐15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 mg every 12 hours for three doses on the first week<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States and Canada (42 centres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5‐15 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoechst Marion Rousel (HMR), Bridgewater, NJ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5‐5 mg every 12 hours for three doses weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Institutes of health, Lederle laboratories and the New England Peabody Home Foundation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States (9 centres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5‐15mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIADDK and by Public Health Service research grants from the Division of Research Resources </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Cross‐over design, only 12 were included in the efficacy analysis and 14 in the safety analysis. </p> <p><sup>b</sup>Placebo: 0.2 mL‐1 mL of normal saline three weekly doses. </p> <p><sup>c</sup>13 patients assigned to received 5 mg/m<sup>2</sup> were excluded from the analyses. </p> <p><sup>d</sup>Second week increased to four doses, third week to five doses, and from the fourth to the 12th six doses. </p> </div> </div> <div class="table" id="CD000957-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient Characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study, Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean Disease Duration (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Females (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous Treatment<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concomitant treatment allowed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, (gold compounds, penicillamine, antimalarials were discontinue 2 months prior entry) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone maintained at the same dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold therapy, D‐penicillamine, Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone (&lt;10mg or equivalent daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 46</p> <p>Placebo: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 1</p> <p>Placebo: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 47.1</p> <p>Placebo: 47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 7.6</p> <p>Placebo: 8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold salts, D‐penicillamine, Cloroquine diphosphate, Sulfasalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Corticosteroids maintained at the same dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 53.3</p> <p>Placebo: 54.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 6.5</p> <p>Placebo: 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other disease modifying anti‐rheumatic drugs except methotrexate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone (&lt;10mg/d or equivalent)</p> <p>Folate 1mg once or twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 60</p> <p>Placebo: 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 8.33</p> <p>Placebo: 10.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold salt therapy, Penicillamine, Hydroxychloroquine and Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stable doses of Aspirin, NSAIDs, Prednisone &lt;10mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 53</p> <p>Placebo: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 14</p> <p>Placebo: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral or oral gold therapy, D‐penicillamine, azathioprine, cyclophosphamide, chlorambucil, antimalarials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stable doses of Aspirin and/or NSAID.</p> <p>Prednisone &lt;10mg/d</p> <p>Analgesics (acetaminophen, propoxyphene, or codeine)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Mean (range) </p> <p><sup>b</sup>These drugs had been discontinued because of ineffectiveness or toxicity. </p> <p><sup>c</sup>All disease modifying anti‐rheumatic drugs were discontinued for at least 30 days before the study entry. </p> </div> </div> <section id="CD000957-sec-0050"> <h5 class="title">Summary of studies</h5> <p><b>Design</b>: there were four parallel group randomised controlled trials (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>) and two trials with a cross‐over design (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>). For <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>, we collected only data on adverse events because no separate data were provided for period 1 (before cross‐over) of the study. There was an additional trial where patients received methotrexate for 12 days and were then blindly randomised to methotrexate (5 or 10 mg/m<sup>2</sup>) or placebo (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>). Randomization ratios included 1:1 (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>), 2:1 (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>) and 3:2:3 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). </p> <p><b>Sample sizes:</b> sample sizes ranged from 15 patients (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>) to 485 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). We excluded 13 patients from <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> who were receiving methotrexate doses less than 7.5 mg every week and 182 patients from <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> receiving leflunomide. At the end, we included 732 patients in our analyses. </p> <p><b>Setting:</b> four of the trials were conducted in the United States (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985;</a><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989;</a><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>), one in United States and Canada (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>), one in China (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>) and one in Brazil (<a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>). Four trials were conducted at single centres (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>) and three trials were multicenter studies conducted at 2, 9, and 42 centres (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). </p> <p><b>Participants:</b> 542 (74%) patients were females. The mean age of patients ranged from 46 to 60 years. Patients were at least 16 years old and met the ACR criteria for RA. Except for <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>, the population in most trials included in the review had severe RA of long duration (mean disease duration ranged from 4.8 to 14 years) and a high prevalence of positive rheumatoid factor (RF). All participants had previously failed other second‐line agents (DMARD) therapy including gold therapy, D‐penicillamine, azathioprine, sulphasalazine, and anti‐malarials. Most were allowed concurrent use of steroids and non‐steroidal anti‐inflammatory drugs (NSAIDs). Common exclusion criteria included active liver disease, history of malignancy, history of renal disease, and presence of other arthritic conditions. </p> <p><b>Interventions:</b> 415 patients received methotrexate monotherapy and 302 received matching placebo. An additional 15 patients in <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> received both methotrexate and matching placebo at different points of time during the study (<a href="#CD000957-tbl-0002">Table 1</a>). Methotrexate was administered orally in six studies and intramuscularly (IM) in one study (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>). Doses ranged between 5 mg and 25 mg per week. In <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> 0.2 ml to 1 ml of normal saline was used as placebo. In the remaining trials matching placebo was used with no proper mention about the type of placebo. </p> <p><b>Duration:</b> the duration of the trials ranged between 12 and 52 weeks. In <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> patients were evaluated every 3 weeks beginning at 5 weeks and then at 8 weeks and 11 weeks. Cross‐over occurred at 14 weeks followed by evaluation at 18, 21, 24 and 27 weeks. In <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> patients entered in a 12‐day in‐patient period and, after randomisation efficacy assessment, were assessed every 4 weeks at 2, 6, 10, 14 and 18 weeks. In <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> patients were followed for 12 weeks. <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> evaluated patients at 12 weeks. In <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> patients were followed every 12 weeks for a 12 months period. In <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> cross‐over occurred at 12 weeks and patients were evaluated at 12 weeks and 24 weeks. In <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> patients were followed at 6, 12 and 18 weeks after initial evaluation at entry into the study. </p> <p><b>Outcomes:</b> generally the trials included most of the OMERACT outcome measures. Reported efficacy outcomes included swollen and tender joint count, swollen and tender joint index, physician global assessment of disease activity, walking time, grip strength, ESR and CRP. Most studies were conducted between 1985 and 1993, before any definitions of improvement were published, thus only one study published in 1999 reported data on the percent of people improving using the ACR core set (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Patient‐reported outcomes included pain, patient global assessment, morning stiffness, health‐related quality of life, and functional status measured by ADL, modified HAQ and HAQ disability index. <a href="#CD000957-tbl-0004">Table 3</a> depicts the scales used for each type of outcome measure. Radiographic evidence of joint damage was assessed only in <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> (Total Sharp score, erosion score, joint space narrowing and radiographic progression defined as an increase in erosion scores of &gt; 3 units). All studies reported adverse events, but <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> did not report number of events for the placebo group. </p> <div class="table" id="CD000957-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Scales used for measuring different outcomes across different studies.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tender Joint Count</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tender Joint Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5+=trace</p> <p>1+=mild pain</p> <p>2+= moderate pain</p> <p>3+=severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ritchie articular index: 0=normal</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Ritchie tender joint index, with a maximum tenderness joint count of 207. Tenderness was scaled from 0=no pain to 3+ =severe pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=no pain, 1=mild pain,</p> <p>2=moderate pain,</p> <p>3=severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=none</p> <p>1=positive response on questioning</p> <p>2=spontaneous response on questioning</p> <p>3=withdrawal by patient on examination</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Swollen Joint Count</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Swollen Joint Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5+= trace</p> <p>1+= mild swelling</p> <p>2+= moderate swelling</p> <p>3+= severe swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ritchie articular index: 0=normal</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Ritchie index but not measuring hips and neck for swelling with a maximum count of 198. Swelling was scaled from 0=no swelling to 3+=severe swelling </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=no swelling, 1=mild swelling,</p> <p>2=moderate swelling,</p> <p>3=severe swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=none</p> <p>1=detectable synovial thickening with loss of bony contours</p> <p>2=loss of distinctness of bony contours</p> <p>3=bulging synovial proliferation with cystic characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Physician global assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0= no change</p> <p>1=minimal improvement</p> <p>2= moderate improvement</p> <p>3=marked improvement</p> <p>4= remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 30% improvement (scale graded from "no effect" to "significantly better")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=asymptomatic</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1=asymptomatic</p> <p>2=mild</p> <p>3=moderate</p> <p>4=severe</p> <p>5=very severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Walking time</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 meters in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CRP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS pain rating scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient global assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS with 0=worst and 10=normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graded from "no effect" to "significantly better". Improvement was defined by at least 1/3 increment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐asymptomatic</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> <p>4=very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1=asymptomatic</p> <p>2=mild</p> <p>3=moderate</p> <p>4=severe</p> <p>5=very severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Work productivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty with work related activities due to health problems and health concerns on a 6‐point scale with 1=none to 6=not done, can't do it. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Morning stiffness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hand grip strength</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>kPa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Activities of daily living (ADL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient's ability to complete 18 activities of daily living on a scale of 1‐10 (maximum score=180) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HAQ disability index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 questions (8 functional categories of 2 or 3 questions) Activities performed on a daily basis </p> <p>Responses: 0=without difficulty to 3=unable to do</p> <p>Scores are summed (0‐24) and divided by the number of categories scored</p> <p>Disability index ranges from 0 to 3</p> <p>Higher scores = more disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MHAQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 questions about functional activities performed on a daily basis</p> <p>Responses: 0=without difficulty to 3=unable to do</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SF‐36 Physical component and mental component</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 scales: physical functioning, role‐physical, bodily pain, general health, vitality, social functioning, role emotional and mental health </p> <p>Higher values indicate better quality of life</p> <p>Scores are transformed to a 0‐100 scale</p> <p>Scales are combined into summary physical and mental component scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Erosion score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 joints in the hands and 12 in the feet</p> <p>The scale for erosions ranged from 0 to 5</p> <p>0 for normal joints and increasing grades for progressively more involvement<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Joint space narrowing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 joints in the hand and 12 in the feet</p> <p>Scale of 0‐4</p> <p>0=normal, 1=asymmetric or minimal narrowing &lt;11%, 2=11‐50%, 3=51‐99% and 4=complete loss of joint space and presumptive ankylosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total Sharp score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erosion + joint space narrowing scores Maximum possible total score of 422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR= Not reported</p> <p><sup>1"</sup>Progression from one grade to the next was scored when a discrete new erosion appeared in a previously uninvolved quadrant of the joint or carpal bone or when a preexisting erosion increased sufficiently in size to be judged greater than what could have occurred because of artifacts caused by changes in position or differences in radiation exposure or film development </p> </div> </div> </section> </section> <section id="CD000957-sec-0051"> <h4 class="title">Excluded studies</h4> <p>Three studies were excluded in the original review (<a href="./references#CD000957-bbs2-0008" title="CannonGW , ReadingJC , WardJR , BlonquistLJ , ColletteLB . Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. Scandinavian Journal of Rheumatology1990;19:285‐94. ">Cannon 1990</a>; <a href="./references#CD000957-bbs2-0011" title="SzantoE . Low‐dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double‐blind randomized study. Scandinavian Journal of Rheumatology1986;15:97‐102. ">Szanto 1986</a>; <a href="./references#CD000957-bbs2-0012" title="ThompsonRN , WattsC , EdelmanJ , EsdaileJ , RussellAS . A controlled two‐centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. Journal of Rheumatology1984;11:760‐3. ">Thompson 1984</a>). For this update an additional 3 studies were excluded (<a href="./references#CD000957-bbs2-0013" title="WeinblattME , MaierAL , FraserPA , CoblynJS . Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Journal of Rheumatology1998;25(2):238‐42. [PUBMED: 9489813] ">Weinblatt 1998</a>, <a href="./references#CD000957-bbs2-0009" title="CohenS , CannonGW , SchiffM , WeaverA , FoxR , OlsenN , et al. Two‐year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis and Rheumatism2001;44(9):1984‐92. [PUBMED: 11592358] ">Cohen 2001</a>, and <a href="./references#CD000957-bbs2-0010" title="JonesG , SebbaA , GuJ , LowensteinMB , CalvoA , Gomez‐ReinoJJ , et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases2010;69(1):88‐96. [PUBMED: 19297346] ">Jones 2010 (AMBITION)</a>). Reasons for exclusion for each study are provided in the <a href="./references#CD000957-sec-0091" title="">Characteristics of excluded studies</a> section. </p> </section> </section> <section id="CD000957-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The judgements about each risk of bias item presented as percentages across all included studies are shown in <a href="#CD000957-fig-0002">Figure 2</a>. The risk of bias summary indicating the judgements about each risk of bias item for each included study is presented in <a href="#CD000957-fig-0003">Figure 3</a>. The trials were generally of moderate to low risk of bias. </p> <div class="figure" id="CD000957-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000957-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000957-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000957-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000957-sec-0053"> <h4 class="title">Allocation</h4> <p>Four studies did not provide details regarding the methods to generate the random sequence and conceal the allocation, and therefore were judged to have unclear risk of bias (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>). <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> used random assignment with random number tables and was considered to have low risk of bias, but not details were provided to evaluate concealment of allocation. <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> employed a computerised adaptive algorithm and was judged to have low risk of bias for both sequence generation and allocation concealment. <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> reported generation of random sequence by a coordinating centre and the allocation was kept by the same centre under a contract. </p> </section> <section id="CD000957-sec-0054"> <h4 class="title">Blinding</h4> <p>All studies were double‐blinded, placebo‐controlled. <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>, even though a double‐blinded, placebo controlled study, is at high risk of bias because during the study one patient developed pancytopenia while receiving methotrexate which required breaking the code during the first arm of the protocol. </p> </section> <section id="CD000957-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were judged to have low risk of bias due to low discontinuation rates and analyses based on an intention‐to‐treat population (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>). Four studies were judged to have high risk of bias where analyses were done in a completers population or no information was provided on withdrawals (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). </p> </section> <section id="CD000957-sec-0056"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> were considered to be at low risk of bias as they have reported all outcomes including adverse events. <a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> was at high risk of bias as adverse events were not reported in the study. </p> </section> <section id="CD000957-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>All the studies were randomized and groups were judged to be balanced at baseline. Five studies reported they were funded by non‐pharmaceutical sources (<a href="#CD000957-tbl-0002">Table 1</a>). For two studies, the source of funding was not reported (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>). </p> </section> </section> <section id="CD000957-sec-0058"> <h3 class="title" id="CD000957-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD000957-tbl-0001"><b>Summary of findings for the main comparison</b> Methotrexate for rheumatoid arthritis</a> </p> <section id="CD000957-sec-0059"> <h4 class="title">Efficacy</h4> <p><i>ACR response</i>: only one study measured the ACR 20 response improvement at 52 weeks (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Patients in the methotrexate group were 1.8 times more likely to improve at least 20% compared to the patients in the placebo group (RR 1.8, 95% CI 1.3 to 2.5) (<a href="./references#CD000957-fig-0004" title="">Analysis 1.1</a>). For ACR 50, patients in the methotrexate group were more likely to have 50% improvement in their symptoms when compared to those in the placebo group (RR 3.0, 95% CI 1.5 to 6.0; absolute treatment benefit (ATB) 15%, 95% CI 8% to 23%) (<a href="./references#CD000957-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). That is, in the methotrexate group 23 people out of 100 had an improvement in their symptoms of at least 50% over 52 weeks, compared to only 8 out of 100 in the placebo group. The NNT was 7 (95% CI 22 to 4). No statistically significant differences were observed between groups for ACR 70 at 52 weeks (<a href="./references#CD000957-fig-0006" title="">Analysis 1.3</a>). </p> <p><i>Remission</i>: <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> categorized patients to be in therapeutic remission if they had at least 5 of (≥ 2 months): morning stiffness of &lt; 15 minutes, no fatigue, no joint pain by history, no joint tenderness, no joint swelling, and Westergren ESR of &lt; 20 mm/hr in men and &lt; 30 mm/hr in women. No patient in either group achieved therapeutic remission (<a href="./references#CD000957-fig-0007" title="">Analysis 1.4</a>). </p> <p><i>Tender and swollen joint counts</i>: four studies assessed the number of tender and swollen joints at 12 to 52 weeks (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). The pooled SMD was ‐0.65 (95% CI ‐0.91 to ‐0.38) (<a href="./references#CD000957-fig-0008" title="">Analysis 1.5</a>). We used <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> data to back‐translate the effect estimate, where the standard deviation of the placebo group at baseline was 6.3. Therefore, on a 28‐joint count people who took methotrexate alone had a further reduction of 4 less tender joints compared with people who took placebo (95% CI 5 to 2). In addition, patients taking methotrexate were more likely to reduce at least by 50% the number of tender joints count when compared to patients taking placebo at 18 weeks (RR 4.2, 95% CI 1.1 to 16.7) (<a href="./references#CD000957-fig-0009" title="">Analysis 1.6</a>). </p> <p>The pooled SMD for the swollen joint counts was ‐0.58 (95% CI ‐0.75 to ‐0.41) (<a href="./references#CD000957-fig-0010" title="">Analysis 1.7</a>). The standard deviation for the placebo group at baseline that was used to back‐translate the effect estimate was 6.2 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Therefore, on a 28‐joint count people who took methotrexate alone had a further reduction of 3 less swollen joints compared with people who took placebo (95% CI 4 to 2). No statistically significant differences were observed in the rates of patients achieving at least 50% reduction in the number of swollen joints (<a href="./references#CD000957-fig-0011" title="">Analysis 1.8</a>). </p> <p><i>Tender and swollen joint indexes</i>: five studies measured joint tenderness and pain index over a time period of 12 to 18 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). The pooled SMD was ‐0.73 (95% CI ‐1.1 to ‐0.34) (<a href="./references#CD000957-fig-0012" title="">Analysis 1.9</a>). The standard deviation for the placebo group at baseline that was used to back‐translate the effect estimate was 31.0 (<a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). Therefore, on a 58‐joint count people who took methotrexate alone had a further reduction of 22 units in their tender joint score compared with people who took placebo (95% CI 34 to 10). Also, patients receiving methotrexate were more likely to achieve at least 30% reduction in joint tenderness and pain index when compared to patients receiving placebo at 12 to 18 weeks (RR 4.3, 95% CI 1.6 to 11.9) (<a href="./references#CD000957-fig-0013" title="">Analysis 1.10</a>). </p> <p>Regarding the swollen joint index, one of the studies provided only one value (per group) for the Ritchie articular index (<a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>). The same values were entered for <a href="./references#CD000957-fig-0012" title="">Analysis 1.9</a> and <a href="./references#CD000957-fig-0014" title="">Analysis 1.11</a>. The pooled SMD was ‐0.48 (95% CI ‐0.70 to ‐0.25) (<a href="./references#CD000957-fig-0014" title="">Analysis 1.11</a>). The standard deviation for the placebo group at baseline that was used to back‐translate the effect estimate was 24.7 (<a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). Therefore, on a 58‐joint count people who took methotrexate alone had a further reduction of 11 units in their swollen joint score compared with people who took placebo (95% CI 17 to 6). Also, patients receiving methotrexate were more likely to achieve at least 30% reduction in joint swelling score when compared to patients receiving placebo (RR 4.9, 95% CI 2.4 to 9.9) (<a href="./references#CD000957-fig-0015" title="">Analysis 1.12</a>). </p> <p><i>Physician global assessment of disease activity</i>: four studies measured this outcome at 12 to 52 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). The pooled SMD was ‐1.1 (95% CI ‐1.5 to ‐0.74) (<a href="./references#CD000957-fig-0016" title="">Analysis 1.13</a>). The standard deviation for the placebo group at baseline that was used to back‐translate the effect estimate was 1.6 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Therefore, on a 0 to 10 scale physicians assessing the methotrexate‐treated group rated a further reduction of 1.8 units in the patients' disease activity compared with the placebo group (95% CI 2.4 to 1.2). No statistically significant differences were observed between groups in the per cent of patients improving the physician global assessment of disease activity by at least by 50% (<a href="./references#CD000957-fig-0017" title="">Analysis 1.14</a>). </p> <p><i>Walking time</i>: four studies measured walking time in seconds at 12 to 18 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). The pooled SMD was ‐0.43 (95% CI ‐0.85 to ‐0.01) (<a href="./references#CD000957-fig-0018" title="">Analysis 1.15</a>). No statistically significant differences were observed in the proportion of patients improving at least by 50% in walking time (<a href="./references#CD000957-fig-0019" title="">Analysis 1.16</a>). </p> <p><i>Grip strength</i>: four studies measured this outcome. No statistically significant differences were found between groups (<a href="./references#CD000957-fig-0020" title="">Analysis 1.17</a>). </p> <p><i>Acute phase reactants</i>: four studies measured ESR at 12 to 52 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>). Patients who received methotrexate lowered their ESR levels by 8.7 units compared to patients who received placebo (95% CI ‐13.9 to ‐3.5) (<a href="./references#CD000957-fig-0021" title="">Analysis 1.18</a>). No statistically significant differences were found for CRP (<a href="./references#CD000957-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD000957-sec-0060"> <h4 class="title">Patient‐reported outcomes</h4> <p><i>Functional status</i>: two studies reported data on HAQ disability index at 12 to 52 weeks (<a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). People who took methotrexate rated the change in their disability to be 0.27 points lower on a scale of 0 to 3 compared with people who took placebo (95% CI ‐0.39 to ‐0.16) (<a href="./references#CD000957-fig-0023" title="">Analysis 2.1</a>; <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). The ATB was ‐9% (95% CI ‐13% to ‐5.3%) and NNT 4 (95% CI 3 to 7). Also, patients on methotrexate were more likely to report improvement of at least 20% or 50% in their HAQ disability index compared to patients on placebo (49% versus 27%; RR 1.8, 95% CI 1.3 to 2.6) and (30% versus 14%; RR 2.2, 95% CI 1.3 to 3.7), respectively (information from single trial: <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>) (<a href="./references#CD000957-fig-0024" title="">Analysis 2.2</a>). </p> <p>The modified HAQ was used in <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>. Patients receiving methotrexate rated the change in their disability to be 0.40 points lower on a scale of 0 to 3 after 52 weeks compared with patients receiving placebo (95% CI ‐0.52 to ‐0.28) (<a href="./references#CD000957-fig-0025" title="">Analysis 2.3</a>). In addition, patients on methotrexate were more likely to report improvement of at least 20% or 50% in their modified HAQ when compared to patients taking placebo (RR 1.7, 95% CI 1.4 to 2.2) (<a href="./references#CD000957-fig-0026" title="">Analysis 2.4</a>). </p> <p>The ADL score was used in <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>. Patients receiving methotrexate rated the change in their disability to be 50 points lower on a scale of 0 to 180 after 18 weeks compared with patients receiving placebo (95% CI ‐67.8 to ‐32.2) (<a href="./references#CD000957-fig-0027" title="">Analysis 2.5</a>). No statistically significant differences were observed between groups in the rate of patients achieving a 50% improvement in ADL scores (<a href="./references#CD000957-fig-0028" title="">Analysis 2.6</a>). </p> <p><i>Health‐related quality of life</i>: quality of life was measured using the SF‐36 by one single trial (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>) at 52 weeks. Patients who were taking methotrexate were more likely to report an improvement of at least 20% or 50% in the SF‐36 physical component when compared to patients taking placebo (39% versus 17%; RR 1.5, 95% CI 1.0 to 2.1) and (23% versus 5%; RR 2.2, 95% CI 1.3 to 3.7), respectively (<a href="./references#CD000957-fig-0029" title="">Analysis 2.7</a>; <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). However, no statistically significant differences were observed between groups for the SF‐36 mental component (<a href="./references#CD000957-fig-0030" title="">Analysis 2.8</a>; <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><i>Pain</i>: four studies measured patient self‐reported pain at 12 to 52 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). People who took methotrexate rated their pain to be 2 points lower on a scale of 0 to 10 after 12 to 52 weeks with methotrexate compared with placebo (95% CI ‐2.4 to ‐1.6) (<a href="./references#CD000957-fig-0031" title="">Analysis 2.9</a>). No statistically significant differences were found in the rates of patients decreasing their pain by at least 50% between groups (information from single trial: <a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>) (<a href="./references#CD000957-fig-0032" title="">Analysis 2.10</a>). No studies reported data on improvement of at least 20% in pain. </p> <p><i>Patient global assessment of disease activity</i>: four studies reported data for this outcome at 12 to 18 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). The pooled SMD was ‐1.2 (95% CI ‐1.6 to ‐0.68) (<a href="./references#CD000957-fig-0033" title="">Analysis 2.11</a>). The standard deviation for the placebo group at baseline that was used to back‐translate the effect estimate was 2.2 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Therefore, on a 0 to 10 scale people who took methotrexate alone had a further reduction of 2.6 units in their global assessment of disease activity compared with people who took placebo (95% CI 3.6 to 1.5). No statistically significant differences were observed between groups in the per cent of patients improving in the patient global assessment of disease activity as defined by the authors (<a href="./references#CD000957-fig-0034" title="">Analysis 2.12</a>). </p> <p><i>Morning stiffness</i>: four studies measured duration of morning stiffness in their study participants over a time period of 12 to 18 weeks (<a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a>; <a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>; <a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a>). No statistically significant differences were observed between groups (<a href="./references#CD000957-fig-0035" title="">Analysis 2.13</a>; <a href="./references#CD000957-fig-0036" title="">Analysis 2.14</a>). </p> <p><i>Work productivity</i>: one trial reported on work productivity (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Patients taking methotrexate were more likely to report at least 20% or 50% improvement in their work productivity when compared to patients taking placebo (RR 1.9, 95% CI 1.2 to 3.1 and RR 2.4, 95% CI 1.2 to 4.7, respectively). That is, only 20 people out 100 in the methotrexate group reported at least 20% improvement in their work productivity compared to 38 people out of 100 in the placebo group. Only 10 people out 100 in the methotrexate group reported at least 50% of improvement in their work productivity compared to 23 people out of 100 in the placebo group (<a href="./references#CD000957-fig-0037" title="">Analysis 2.15</a>). </p> </section> <section id="CD000957-sec-0061"> <h4 class="title">Structural damage</h4> <p><i>Radiographic progression</i>: one trial reported Sharp radiographic scores (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). Patients receiving methotrexate were less likely to have an increase in Sharp erosion scores of more than three units when compared to patients taking placebo (RR 0.31, 95% CI 0.11 to 0.86) (<a href="./references#CD000957-fig-0038" title="">Analysis 3.1</a>). Only 4 people out 100 in the methotrexate group had radiographic progression compared to 12 people out of 100 in the placebo group (ATB ‐8%, 95% CI ‐16% to ‐1%) (<a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><i>T</i> <i>otal Sharp score, erosion score and joint space narrowing</i>: only one study reported data on these outcomes (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>). No statistically significant differences were observed between groups at 52 weeks (<a href="./references#CD000957-fig-0039" title="">Analysis 3.2</a>; <a href="./references#CD000957-fig-0040" title="">Analysis 3.3</a>; <a href="./references#CD000957-fig-0041" title="">Analysis 3.4</a>). </p> <p><i>New joint erosions</i>: the proportion of patients with new joint erosions at 52 weeks were similar between groups (<a href="./references#CD000957-fig-0042" title="">Analysis 3.5</a>). </p> </section> <section id="CD000957-sec-0062"> <h4 class="title">Discontinuations</h4> <p><i>Total number of discontinuations</i>: patients in the methotrexate group were statistically significantly less likely to withdraw for any reason compared with the placebo group (RR 0.73, 95% CI 0.62 to 0.88) (<a href="./references#CD000957-fig-0043" title="">Analysis 4.1</a>). </p> <p><i>Due to lack of efficacy and other reasons</i>: similar rates of discontinuations due to lack of efficacy and other reasons including losses to follow‐up, non‐compliance, protocol violation, and voluntary or unclear reasons were observed between groups (<a href="./references#CD000957-fig-0044" title="">Analysis 4.2</a>; <a href="./references#CD000957-fig-0046" title="">Analysis 4.4</a>; <a href="./references#CD000957-fig-0047" title="">Analysis 4.5</a>; <a href="./references#CD000957-fig-0048" title="">Analysis 4.6</a>; <a href="./references#CD000957-fig-0049" title="">Analysis 4.7</a>). </p> <p><i>Due to adverse events</i>: patients treated with methotrexate were statistically significantly more likely to discontinue treatment and withdraw from the study due to adverse events compared to patients treated with placebo (RR 2.1, 95% CI 1.3 to 3.3) (<a href="./references#CD000957-fig-0045" title="">Analysis 4.3</a>). In the methotrexate group 16 patients out of 100 withdrew due to adverse events over 52 weeks, compared to 8 people out of 100 in the placebo group (95% CI 10 to 25) (ATB 9%, 95% CI 3% to 14%) (<a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). Furthermore, patients in the methotrexate group were more likely to discontinue treatment because of liver enzyme abnormalities compared to patients in the placebo group at 12 to 52 weeks (8% versus 2%; RR 3.8, 95% CI 1.6 to 8.8) (<a href="./references#CD000957-fig-0056" title="">Analysis 4.14</a>). Rates of withdrawals due to other adverse events including alopecia, gastrointestinal events, hematological events, hypertension, infection, interstitial pneumonitis, mucocutaneous events, myocardial infarction and rash were similar between groups (<a href="./references#CD000957-fig-0050" title="">Analysis 4.8</a>; <a href="./references#CD000957-fig-0051" title="">Analysis 4.9</a>; <a href="./references#CD000957-fig-0052" title="">Analysis 4.10</a>; <a href="./references#CD000957-fig-0053" title="">Analysis 4.11</a>; <a href="./references#CD000957-fig-0054" title="">Analysis 4.12</a>; <a href="./references#CD000957-fig-0055" title="">Analysis 4.13</a>; <a href="./references#CD000957-fig-0057" title="">Analysis 4.15</a>; <a href="./references#CD000957-fig-0058" title="">Analysis 4.16</a>; <a href="./references#CD000957-fig-0059" title="">Analysis 4.17</a>). </p> </section> <section id="CD000957-sec-0063"> <h4 class="title">Toxicity</h4> <p><i>Total adverse events</i>: patients in the methotrexate group were more likely to have any type of adverse event compared with the placebo group (RR 3.0, 95% CI 1.4 to 6.4). In the placebo group 15 people out of 100 had adverse events over 12 to 18 weeks, compared to 45 (95% CI 21 to 95) out of 100 for the methotrexate group (<a href="./references#CD000957-fig-0060" title="">Analysis 5.1</a>). </p> <p><i>Serious adverse events</i>: only 2% to 3% of the patients withdrew from the studies at 27 to 52 weeks due to serious adverse events (2% placebo, 3% methotrexate). There was only one study with one death reported in the methotrexate group caused by sepsis, but it was not clear if this was attributed to the drug. No statistically significant differences between groups were observed in the proportion of patients with serious adverse events at 27 to 52 weeks (<a href="./references#CD000957-fig-0061" title="">Analysis 5.2</a>; <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><i>Statistically significant adverse events</i>: patients who received methotrexate were more likely to have an infection when compared to patients who received placebo, at 12 to 52 weeks (49% versus 35%; RR 1.3, 95% CI 1.0 to 1.6) (<a href="./references#CD000957-fig-0077" title="">Analysis 5.18</a>). The most common infections were: upper respiratory infections, bronchitis and pneumonia. Rates of any type of liver enzyme abnormalities were higher in the methotrexate‐treated group compared to the placebo‐treated group at 12 to 52 weeks (15% versus 3%; RR 4.8, 95% CI 2.3 to 10.0) (<a href="./references#CD000957-fig-0078" title="">Analysis 5.19</a>). Stomatitis and oral ulcers at 12 to 18 weeks were more likely to be reported in the methotrexate group compared to the placebo group (9% versus 4%; RR 2.0, 95% CI 1.0 to 4.0) (<a href="./references#CD000957-fig-0087" title="">Analysis 5.28</a>). Also, alopecia and gastrointestinal distress rates were higher in the methotrexate group compared to the placebo group at 12 to 52 weeks (6% versus 1% (<a href="./references#CD000957-fig-0063" title="">Analysis 5.4</a>) and 9% versus 4% (<a href="./references#CD000957-fig-0073" title="">Analysis 5.14</a>), respectively). </p> <p><i>Other reported adverse events</i>: non‐statistically significant differences in the rates of the following adverse events were observed between groups. </p> <p> <ul id="CD000957-list-0001"> <li> <p>Abdominal pain at 12 to 52 weeks (<a href="./references#CD000957-fig-0062" title="">Analysis 5.3</a>). </p> </li> <li> <p>Anorexia at 12 weeks (<a href="./references#CD000957-fig-0064" title="">Analysis 5.5</a>). </p> </li> <li> <p>Allergic reactions at 52 weeks (<a href="./references#CD000957-fig-0065" title="">Analysis 5.6</a>). </p> </li> <li> <p>Back pain at 12 weeks (<a href="./references#CD000957-fig-0066" title="">Analysis 5.7</a>). </p> </li> <li> <p>Chest pain at 12 weeks (<a href="./references#CD000957-fig-0067" title="">Analysis 5.8</a>). </p> </li> <li> <p>Central nervous system (CNS) side effects (nightmares and depression) at 12 to 18 weeks (<a href="./references#CD000957-fig-0068" title="">Analysis 5.9</a>). </p> </li> <li> <p>Cough at 12 to 18 weeks (<a href="./references#CD000957-fig-0069" title="">Analysis 5.10</a>). </p> </li> <li> <p>Deaths at 12 weeks (<a href="./references#CD000957-fig-0070" title="">Analysis 5.11</a>). </p> </li> <li> <p>Diarrhea at 12 to 52 weeks (<a href="./references#CD000957-fig-0071" title="">Analysis 5.12</a>). </p> </li> <li> <p>Dyspepsia at 18 to 52 weeks (<a href="./references#CD000957-fig-0072" title="">Analysis 5.13</a>). </p> </li> <li> <p>Headache at 12 weeks (<a href="./references#CD000957-fig-0074" title="">Analysis 5.15</a>). </p> </li> <li> <p>Hematological adverse events at 18 weeks (<a href="./references#CD000957-fig-0075" title="">Analysis 5.16</a>). </p> </li> <li> <p>Hypertension at 52 weeks (<a href="./references#CD000957-fig-0076" title="">Analysis 5.17</a>). </p> </li> <li> <p>Mucosal ulcers at 18 weeks (<a href="./references#CD000957-fig-0079" title="">Analysis 5.20</a>). </p> </li> <li> <p>Nausea or vomiting, or both, at 12 to 52 weeks (<a href="./references#CD000957-fig-0080" title="">Analysis 5.21</a>). </p> </li> <li> <p>New onset of hypertension at 52 weeks (<a href="./references#CD000957-fig-0081" title="">Analysis 5.22</a>). </p> </li> <li> <p>Proteinuria at 12 weeks (<a href="./references#CD000957-fig-0082" title="">Analysis 5.23</a>). </p> </li> <li> <p>Pruritus at 18 weeks (<a href="./references#CD000957-fig-0083" title="">Analysis 5.24</a>). </p> </li> <li> <p>Psoriasis at 18 weeks (<a href="./references#CD000957-fig-0084" title="">Analysis 5.25</a>). </p> </li> <li> <p>Pulmonary infiltrates (interstitial pneumonitis) at 18 weeks (<a href="./references#CD000957-fig-0085" title="">Analysis 5.26</a>). </p> </li> <li> <p>Rash at 12 to 18 weeks (<a href="./references#CD000957-fig-0086" title="">Analysis 5.27</a>). </p> </li> <li> <p>Stroke at 12 weeks (<a href="./references#CD000957-fig-0088" title="">Analysis 5.29</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000957-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000957-sec-0064"></div> <section id="CD000957-sec-0065"> <h3 class="title" id="CD000957-sec-0065">Summary of main results</h3> <p>Methotrexate was initially used for the treatment of RA in 1951 (<a href="./references#CD000957-bbs2-0022" title="GubnerR , AugustS , GinsburgV . Therapeutic suppression of tissue reactivity.II. Effects of aminopterin in rheumatoid arthritis and psoriasis. American Journal of Medicine1951;221(2):176‐82. ">Gubner 1951</a>). Since then, several open studies, randomized controlled trials (RCTs) and controlled clinical trials (CCTs) have suggested beneficial effects. The purpose of this systematic review was to evaluate the efficacy and toxicity of methotrexate for the treatment of people with RA when compared to placebo. We only included in this review placebo controlled CCTs and RCTs reporting results after a minimum of 12 weeks of treatment. The dosage of methotrexate in these trials ranged from 7.5 to 25 mg per week. </p> <p>Substantial differences between placebo and methotrexate were observed for measures of disease activity, in favour of methotrexate. These differences were clinically important and statistically significant for various efficacy and patient‐reported outcomes and structural damage measures. The standardized weighted differences between methotrexate and placebo for the various outcome measures varied between ‐0.43 and ‐1.2. These effects can be considered to be substantial. The minimum effect size considered to be clinically meaningful in RA has been estimated at 0.30 (<a href="./references#CD000957-bbs2-0026" title="KazisLEE , AndersonJJ , MeenanRF . Effect sizes for interpreting changes in health status. Medical Care1989;27(S3):S178‐89. ">Kazis 1989</a>). The absolute treatment benefit (ATB) to achieve an ACR20 response was 20% and for an ACR50 was 15% with a NNT of 6 and 7, respectively. No statistically significant differences were observed in the overall number of withdrawals and dropouts, but methotrexate participants were statistically significantly more likely to discontinue treatment because of adverse reactions, specifically liver enzyme abnormalities and placebo participants because of lack of response. The most frequent side effects with methotrexate were infections, raised liver enzymes and stomatitis. </p> </section> <section id="CD000957-sec-0066"> <h3 class="title" id="CD000957-sec-0066">Overall completeness and applicability of evidence</h3> <p>Two new studies were included for this update (<a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a>; <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>. However, most studies were conducted between 1985 and 1993, before any definitions of improvement were published, thus only one study published in 1999 (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>) reported data on the per cent of people improving using the ACR core set. Evidence on radiographic outcomes was also derived from the same unique study (<a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a>), which showed statistically significant delay in progression with methotrexate. This trial used state of the art study design and recommended outcome measures for trials in RA (<a href="./references#CD000957-bbs2-0018" title="FelsonDT , AndersonJJ , BoersM , et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism1993;36:729‐40. ">Felson 1993</a>; <a href="./references#CD000957-bbs2-0028" title="OMERACT . Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology1993;20:526‐91. ">OMERACT 1993</a>). This updated review provides confirmatory evidence of the benefit of methotrexate at weekly doses of 5 to 25 mg for patients with RA. The trials included in this review used similar inclusion criteria and the participant populations had longstanding severe RA (more than 4 years), were often seropositive, and had failed previous DMARDs (for example, gold therapy, D‐penicillamine, anti‐malarials). Despite the severity of the disease, the improvement was substantial. Both cross‐over trials reported a failure in the disease state after discontinuation of methotrexate, which suggests that the drug has to be continued to maintain the benefit. The long term effectiveness or safety profile of methotrexate cannot be established with this review. </p> </section> <section id="CD000957-sec-0067"> <h3 class="title" id="CD000957-sec-0067">Quality of the evidence</h3> <p>The <a href="./full#CD000957-tbl-0001">summary of findings Table for the main comparison</a> shows the overall quality of evidence. Evidence quality was mainly moderate to high with one outcome, remission, being graded as low quality. Statistically significant heterogeneity among trials was observed for various outcome measures. The heterogeneity remained significant with random‐effects models. As expected, random‐effects model pooling resulted in larger confidence intervals than those obtained from fixed‐effect models. Nevertheless, most efficacy outcome measures remained statistically significant. The reasons for heterogeneity are not apparent but are not likely to relate to the RA populations in the trials since participants were quite similar, having longstanding and severe RA. More likely, differences may have resulted from the various methods used to estimate these outcomes, which requires standardization. For instance, global assessments were measured in different trials with Likert scales or visual analogue scales (VAS). </p> </section> <section id="CD000957-sec-0068"> <h3 class="title" id="CD000957-sec-0068">Potential biases in the review process</h3> <p>A strength of this review is the electronic search strategy using the latest methodology. All important databases were searched, including trial registers. Two trials used a cross‐over design (<a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>). Because of how the data were reported, we used the final results for the first arm, which was provided only in <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>. In two trials (<a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a>; <a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a>) we used the baseline standard deviation to pool the results. This procedure may have created some bias. It was similarly applied to both groups (treatment and control) and the overall impact on the estimation of differences between groups is probably small. Moreover, this bias is expected to result in decreased weighting of these studies, which was preferable, in our view, to excluding the trials. </p> </section> <section id="CD000957-sec-0069"> <h3 class="title" id="CD000957-sec-0069">Agreements and disagreements with other studies or reviews</h3> <p>Clinical practice guidelines recommend methotrexate to be used as a first DMARD in the majority of patients with RA (<a href="./references#CD000957-bbs2-0032" title="SinghJA , FurstDE , BharatA , CurtisJR , KavanaughAF , KremerJM , et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research (Hoboken)2012;64(5):625‐39. ">Singh 2012</a>; <a href="./references#CD000957-bbs2-0033" title="SmolenJS , LandewéR , BreedveldFC , BuchM , BurmesterG , DougadosM , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases2013;Oct 25:doi: 10.1136/annrheumdis‐2013‐204573. ">Smolen 2013</a>). Other published meta‐analyses have reported similar results (<a href="./references#CD000957-bbs2-0017" title="FelsonDT , AndersonJJ , MeenanRF . Use of short‐term efficacy/toxicity tradeoffs to select second‐line drugs in rheumatoid arthritis. A meta‐analysis of published clinical trials. Arthritis and Rheumatism1992;35:1117‐25. ">Felson 1992</a>; <a href="./references#CD000957-bbs2-0020" title="GøtzschePC , PødenphantJ , OlesenM , HalbergP . Meta‐analysis of second‐line antirheumatic drugs: sample size bias and uncertain benefit. Journal of Clinical Epidemiology1992;45(6):587‐94. [PUBMED: 1535101] ">Gotzsche 1992</a>) but the studies included in these reviews did not include state of the art study design nor used the patient responder analyses as recommended by OMERACT (as reported in the <a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> study). These systematic reviews also concluded that methotrexate has a better benefit‐harm ratio compared to other alternatives. Furthermore, methotrexate has been proven to be effective even if re‐employed after previous failure (<a href="./references#CD000957-bbs2-0025" title="KapralT , StammT , MacholdKP , MontagK , SmolenJS , AletahaD . Methotrexate in rheumatoid arthritis is frequently effective, even if re‐employed after a previous failure. Arthritis Research &amp; Therapy2006;8(2):R46. [PUBMED: 16507172] ">Kapral 2006</a>). </p> <p>Long term extensions of clinical trials have reported similar findings (<a href="./references#CD000957-bbs2-0013" title="WeinblattME , MaierAL , FraserPA , CoblynJS . Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Journal of Rheumatology1998;25(2):238‐42. [PUBMED: 9489813] ">Weinblatt 1998</a>; <a href="./references#CD000957-bbs2-0038" title="WeinsteinA , MarloweS , KornJ , FarouharF . Low‐dose methotrexate treatment of rheumatoid arthritis. Long‐term observations. American Journal of Medicine1985;79(3):331‐7. [PUBMED: 4036984] ">Weinstein 1985</a>). <a href="./references#CD000957-bbs2-0013" title="WeinblattME , MaierAL , FraserPA , CoblynJS . Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Journal of Rheumatology1998;25(2):238‐42. [PUBMED: 9489813] ">Weinblatt 1998</a> found that after 11 years of receiving methotrexate monotherapy only 11% of 26 patients discontinued due to toxicity. <a href="./references#CD000957-bbs2-0038" title="WeinsteinA , MarloweS , KornJ , FarouharF . Low‐dose methotrexate treatment of rheumatoid arthritis. Long‐term observations. American Journal of Medicine1985;79(3):331‐7. [PUBMED: 4036984] ">Weinstein 1985</a> evaluated 21 patients for five years and only two discontinued therapy due to gastrointestinal toxicity. In the TEMPO trial after three years of methotrexate exposure in 228 patients, non‐infectious serious adverse events were reported in 23% of the patients (<a href="./references#CD000957-bbs2-0037" title="van derHeijdeD , KlareskogL , LandewéR , BruynGA , CantagrelA , DurezP , et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism2007;56(1):3928‐39. [PUBMED: 18050208] ">van der Heijde 2007</a>). Furthermore, a systematic review of 2008 to 2012 literature that was conducted for the Italian clinical recommendations for the use of methotrexate in rheumatic diseases found evidence suggesting that discontinuation rates due to toxicity are similar to those in patients treated with hydroxychloroquine or leflunomide, and lower than those in patients receiving gold salts or sulphasalazine (<a href="./references#CD000957-bbs2-0035" title="TodoertiM , MaglioneW , BerneroE , BortoluzziA , ColaciM , GaluppiE , et al. Systematic review of 2008‐2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo2013;65(5):207‐18. [PUBMED: 24399184] ">Todoerti 2013</a>). The most frequent adverse events reported in the 70 included studies were gastrointestinal and liver toxicity, especially during the first five years. The discontinuation rate due to hepatotoxicity is about 5%. Nonetheless, a recently updated Cochrane review has found that when supplemented with folic acid, methotrexate side effects can be reduced (<a href="./references#CD000957-bbs2-0030" title="SheaB , SwindenMV , Tanjong GhogomuE , OrtizZ , KatchamartW , RaderT , et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews2013;5(CD000951):doi: 10.1002/14651858.CD000951.pub2.. [PUBMED: 23728635] ">Shea 2003</a>; <a href="./references#CD000957-bbs2-0031" title="SheaB , SwindenMV , Tanjong GhogomuE , OrtizZ , KatchamartW , RaderT , et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews2013;5:CD000951. [DOI: 10.1002/14651858.CD000951.pub2] ">Shea 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000957-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of the included studies.*Additional data were unavailable since at the time of the publication this information was not required to be reported." data-id="CD000957-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of the included studies.</p> <p>*Additional data were unavailable since at the time of the publication this information was not required to be reported. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000957-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000957-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 1 ACR 20." data-id="CD000957-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 1 ACR 20.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 2 ACR 50." data-id="CD000957-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 2 ACR 50.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 3 ACR 70." data-id="CD000957-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 3 ACR 70.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 4 Disease Remission." data-id="CD000957-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 4 Disease Remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 5 Number of tender joints." data-id="CD000957-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 5 Number of tender joints.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 6 &gt;50% improvement in TJC." data-id="CD000957-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 6 &gt;50% improvement in TJC.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 7 Number of swollen joints." data-id="CD000957-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 7 Number of swollen joints.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 8 &gt;50% improvement in SJC." data-id="CD000957-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 8 &gt;50% improvement in SJC.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 9 Tender Joint Score/Index." data-id="CD000957-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 9 Tender Joint Score/Index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 10 at least 30% improvement in TJS." data-id="CD000957-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 10 at least 30% improvement in TJS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 11 Swollen Joint Score/Index." data-id="CD000957-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 11 Swollen Joint Score/Index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 12 at least 30% improvement in SJS." data-id="CD000957-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 12 at least 30% improvement in SJS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 13 Physician global assessment." data-id="CD000957-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 13 Physician global assessment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 14 Percent of patients improving in PhGA." data-id="CD000957-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 14 Percent of patients improving in PhGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 15 Walking time." data-id="CD000957-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 15 Walking time.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 16 &gt;50% improvement in walking time." data-id="CD000957-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 16 &gt;50% improvement in walking time.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 17 Grip strength." data-id="CD000957-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 17 Grip strength.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 18 ESR." data-id="CD000957-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 18 ESR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 19 CRP." data-id="CD000957-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 19 CRP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 1 HAQ Disability Index." data-id="CD000957-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 1 HAQ Disability Index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 2 Percent of improvement in HAQ‐Di." data-id="CD000957-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 2 Percent of improvement in HAQ‐Di.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 3 MHAQ." data-id="CD000957-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 3 MHAQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 4 Percent of improvement in MHAQ." data-id="CD000957-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 4 Percent of improvement in MHAQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 5 Activities of Daily Living (ADL)." data-id="CD000957-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 5 Activities of Daily Living (ADL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 6 Activities of Daily Living (ADL)." data-id="CD000957-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 6 Activities of Daily Living (ADL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 7 SF‐36 Physical component." data-id="CD000957-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 7 SF‐36 Physical component.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 8 SF‐36 Mental component." data-id="CD000957-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 8 SF‐36 Mental component.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 9 Pain." data-id="CD000957-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 9 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 10 Pain." data-id="CD000957-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 10 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 11 Patient global assessment." data-id="CD000957-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 11 Patient global assessment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 12 Improvement in PtGA." data-id="CD000957-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 12 Improvement in PtGA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 13 Morning stiffness." data-id="CD000957-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 13 Morning stiffness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 14 Morning stiffness." data-id="CD000957-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 14 Morning stiffness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Patient‐reported outcomes, Outcome 15 Work Productivity." data-id="CD000957-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Patient‐reported outcomes, Outcome 15 Work Productivity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Radiographic outcomes, Outcome 1 Radiographic Progression." data-id="CD000957-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Radiographic outcomes, Outcome 1 Radiographic Progression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Radiographic outcomes, Outcome 2 Total Sharp Score." data-id="CD000957-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Radiographic outcomes, Outcome 2 Total Sharp Score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Radiographic outcomes, Outcome 3 Erosion Score." data-id="CD000957-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Radiographic outcomes, Outcome 3 Erosion Score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Radiographic outcomes, Outcome 4 Joint Space Narrowing." data-id="CD000957-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Radiographic outcomes, Outcome 4 Joint Space Narrowing.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Radiographic outcomes, Outcome 5 New Joint Erosions." data-id="CD000957-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Radiographic outcomes, Outcome 5 New Joint Erosions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 1 Total." data-id="CD000957-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 1 Total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 2 Lack of efficacy." data-id="CD000957-fig-0044" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 2 Lack of efficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 3 Adverse events." data-id="CD000957-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 4 Lost to follow‐up." data-id="CD000957-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 4 Lost to follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 5 Non‐compliance." data-id="CD000957-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 5 Non‐compliance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 6 Protocol violation." data-id="CD000957-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 6 Protocol violation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 7 Voluntary or unclear reasons." data-id="CD000957-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 7 Voluntary or unclear reasons.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 8 Alopecia." data-id="CD000957-fig-0050" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 8 Alopecia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 9 Gastrointestinal adverse events." data-id="CD000957-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 9 Gastrointestinal adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 10 Hematological adverse events." data-id="CD000957-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 10 Hematological adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 11 Hypertension." data-id="CD000957-fig-0053" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 11 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 12 Infection." data-id="CD000957-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 12 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 13 Interstitial pneumonitis/Pulmonary infiltrates." data-id="CD000957-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 13 Interstitial pneumonitis/Pulmonary infiltrates.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 14 Liver enzyme abnormalities." data-id="CD000957-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 14 Liver enzyme abnormalities.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 15 Mucocutaneous adverse events." data-id="CD000957-fig-0057" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 15 Mucocutaneous adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 16 Myocardial infarction." data-id="CD000957-fig-0058" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 16 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuations, Outcome 17 Rash." data-id="CD000957-fig-0059" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Discontinuations, Outcome 17 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 1 Total." data-id="CD000957-fig-0060" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 1 Total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 2 Serious Adverse Events." data-id="CD000957-fig-0061" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 2 Serious Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 3 Abdominal pain." data-id="CD000957-fig-0062" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 3 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 4 Alopecia." data-id="CD000957-fig-0063" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 4 Alopecia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 5 Anorexia." data-id="CD000957-fig-0064" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 5 Anorexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 6 Allergic reactions." data-id="CD000957-fig-0065" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 6 Allergic reactions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 7 Backpain." data-id="CD000957-fig-0066" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 7 Backpain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 8 Chest pain." data-id="CD000957-fig-0067" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 8 Chest pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 9 CNS (Nightmares, Depression)." data-id="CD000957-fig-0068" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 9 CNS (Nightmares, Depression).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 10 Cough." data-id="CD000957-fig-0069" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 10 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 11 Death." data-id="CD000957-fig-0070" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 11 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 12 Diarrhea." data-id="CD000957-fig-0071" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 12 Diarrhea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 13 Dyspepsia." data-id="CD000957-fig-0072" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 13 Dyspepsia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 14 Gastroenteritis/gastrointestinal distress." data-id="CD000957-fig-0073" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 14 Gastroenteritis/gastrointestinal distress.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 15 Headache." data-id="CD000957-fig-0074" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 15 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 16 Hematological adverse events." data-id="CD000957-fig-0075" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 16 Hematological adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 17 Hypertension." data-id="CD000957-fig-0076" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 17 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 18 Infections." data-id="CD000957-fig-0077" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 18 Infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 19 Liver enzymes abnormalities." data-id="CD000957-fig-0078" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 19 Liver enzymes abnormalities.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 20 Mucosal ulcers." data-id="CD000957-fig-0079" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 20 Mucosal ulcers.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 21 Nausea and/or Vomiting." data-id="CD000957-fig-0080" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 21 Nausea and/or Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 22 New onset Hypertension." data-id="CD000957-fig-0081" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 22 New onset Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 23 Proteinuria." data-id="CD000957-fig-0082" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 23 Proteinuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 24 Pruritus." data-id="CD000957-fig-0083" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 24 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 25 Psoriasis." data-id="CD000957-fig-0084" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 25 Psoriasis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 26 Pulmonary events." data-id="CD000957-fig-0085" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 26 Pulmonary events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 27 Rash." data-id="CD000957-fig-0086" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 27 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 28 Stomatitis/oral ulcers." data-id="CD000957-fig-0087" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 28 Stomatitis/oral ulcers.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000957-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/urn:x-wiley:14651858:media:CD000957:CD000957-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_t/tCD000957-CMP-005-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 29 Stroke." data-id="CD000957-fig-0088" src="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 29 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/media/CDSR/CD000957/image_n/nCD000957-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000957-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate for rheumatoid arthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Methotrexate for rheumatoid arthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with rheumatoid arthritis<br/> <b>Settings:</b> rheumatology clinics<br/> <b>Intervention:</b> methotrexate (weekly doses ranging between 5 mg and 25 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="2" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b> Methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ACR 50</b> <br/> American College of Rheumatology improvement criteria<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> <br/> (12 to 46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.0</b> <br/> (1.5 to 6.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute treatment benefit 15% (95% CI 8% to 23%); Relative percent change 203% (95% CI 53% to 498%); NNTB 7 (95% CI 4 to 22); <a href="./references#CD000957-fig-0005" title="">Analysis 1.2</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Remission</b><sup>3</sup> </p> <p>Follow‐up: 18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant. No patients in either group met the remission criteria</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Functional Status</b> <br/> Health Assessment Questionnaire Disability Index . Scale from: 0 to 3<br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean functional status ranged across control groups from<br/> <b>0.53‐1.34 units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean functional status in the intervention groups was<br/> <b>0.27 lower</b> <br/> (0.39 to 0.16 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit ‐9% (95% CI ‐13% to ‐5.3%); Relative percent change 20% (95% CI 29% to 12%); <a href="./references#CD000957-fig-0023" title="">Analysis 2.1</a>The reported final mean scores in the methotrexate group was 1.0 and in the placebo group 1.3. NNTB 4 (95% CI 3 to 7)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Health‐Related Quality of Life</b> </p> <p>at least 20% improvement<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SF‐36</b> Physical Component </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 per 100</b> <br/> (27 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> <br/> (1 to 2.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit 12% (95% CI 1% to 24%); Relative percent change 45% (95% CI 0% to 112%); NNTB 9 (95% CI 4 to 539); <a href="./references#CD000957-fig-0029" title="">Analysis 2.7</a> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>SF‐36</b> Mental Component </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 100</b> </p> <p>(16 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.3</b> <br/> (0.79 to 2.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant; Absolute treatment benefit 5% (95% CI ‐5% to 16%); Relative percent change 25% (95% CI ‐21% to 98%); <a href="./references#CD000957-fig-0030" title="">Analysis 2.8</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Radiographic Progression</b> <br/> Increase in erosion scores of &gt; 3 units<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (1 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.31</b> <br/> (0.11 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit ‐8% (95% CI ‐16% to ‐1%); Relative percent change ‐69% (95% CI ‐89% to ‐14%); NNTB 13 (95% CI 10 to 60); <a href="./references#CD000957-fig-0038" title="">Analysis 3.1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Discontinuations</b> <br/> <b>due to adverse events</b> </p> <p>Follow‐up: 12‐52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 per 100</b> <br/> (10 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.1</b> <br/> (1.3 to 3.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>613<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute treatment benefit 9% (95% CI 3% to 14%); Relative percent change 106% (95% CI 30% to 225%); NNTH 13 (95% CI 6 to 44); <a href="./references#CD000957-fig-0045" title="">Analysis 4.3</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious Adverse Events</b> <br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.4</b> <br/> (0.36 to 5.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant; Absolute treatment benefit 1% (95% CI ‐3% to 4%); Relative percent change 44% (95% CI ‐64% to 474%); <a href="./references#CD000957-fig-0061" title="">Analysis 5.2</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Only one study reported this outcome. Probability of publication bias: published evidence is limited to a small number of trials, all of which are showing benefits of the studied intervention. </p> <p><sup>2</sup>Limitations in the design and implementation of available studies suggesting high likelihood of bias. Analysis was performed in the completers population and the discontinuation rate was higher than 20%<br/> <sup>3</sup><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> categorized patients to be in therapeutic remission if they had at least 5 of (≥2 months): morning stiffness of &lt;15 minutes, no fatigue, no joint pain by history, no joint tenderness, no joint swelling, and Westergren ESR of &lt;20 mm/hr in men and &lt;30 mm/hr in women. </p> <p><sup>4</sup><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> used as the control group baseline mean and control group standard deviation for calculations. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate for rheumatoid arthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000957-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study, year</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Sample size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country (# sites)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up duration</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Methotrexate dose, frequency and route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Funding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Methotrexate</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Placebo</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>15<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States (2 centres)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐25 mg IM weekly doses<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grant from Veterans administration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 mg/m<sup>2c</sup>, 10 mg/m<sup>2</sup> orally, weekly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRC Grant RR59 and Lederle laboratories</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 mg‐15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 mg every 12 hours for three doses on the first week<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>United States and Canada (42 centres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5‐15 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoechst Marion Rousel (HMR), Bridgewater, NJ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States (single centre)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5‐5 mg every 12 hours for three doses weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Institutes of health, Lederle laboratories and the New England Peabody Home Foundation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States (9 centres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5‐15mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIADDK and by Public Health Service research grants from the Division of Research Resources </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Cross‐over design, only 12 were included in the efficacy analysis and 14 in the safety analysis. </p> <p><sup>b</sup>Placebo: 0.2 mL‐1 mL of normal saline three weekly doses. </p> <p><sup>c</sup>13 patients assigned to received 5 mg/m<sup>2</sup> were excluded from the analyses. </p> <p><sup>d</sup>Second week increased to four doses, third week to five doses, and from the fourth to the 12th six doses. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000957-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient Characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study, Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean Disease Duration (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Females (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous Treatment<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concomitant treatment allowed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, (gold compounds, penicillamine, antimalarials were discontinue 2 months prior entry) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone maintained at the same dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold therapy, D‐penicillamine, Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone (&lt;10mg or equivalent daily)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 46</p> <p>Placebo: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 1</p> <p>Placebo: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 47.1</p> <p>Placebo: 47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 7.6</p> <p>Placebo: 8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold salts, D‐penicillamine, Cloroquine diphosphate, Sulfasalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Corticosteroids maintained at the same dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 53.3</p> <p>Placebo: 54.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 6.5</p> <p>Placebo: 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other disease modifying anti‐rheumatic drugs except methotrexate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NSAIDs, Prednisone (&lt;10mg/d or equivalent)</p> <p>Folate 1mg once or twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 60</p> <p>Placebo: 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 8.33</p> <p>Placebo: 10.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gold salt therapy, Penicillamine, Hydroxychloroquine and Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stable doses of Aspirin, NSAIDs, Prednisone &lt;10mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 53</p> <p>Placebo: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MTX: 14</p> <p>Placebo: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral or oral gold therapy, D‐penicillamine, azathioprine, cyclophosphamide, chlorambucil, antimalarials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stable doses of Aspirin and/or NSAID.</p> <p>Prednisone &lt;10mg/d</p> <p>Analgesics (acetaminophen, propoxyphene, or codeine)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Mean (range) </p> <p><sup>b</sup>These drugs had been discontinued because of ineffectiveness or toxicity. </p> <p><sup>c</sup>All disease modifying anti‐rheumatic drugs were discontinued for at least 30 days before the study entry. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Patient Characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000957-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Scales used for measuring different outcomes across different studies.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0001" title="AndersenPA , WestSG , O'DellJR , ViaCS , ClaypoolRG , KotzinBL . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double‐blind study. Annals of Internal Medicine1985;103(4):489‐96. ">Andersen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0004" title="PinheiroGR , Helfenstein JuniorM , FerrazMB , AtraE . [A short‐term randomized controlled study with methotrexate in rheumatoid arthritis]. [Portuguese]. Revista Da Associacao Medica Brasileira1993;39(2):91‐4. ">Pinheiro 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0002" title="FurstDE , EriksonN , CluteL , KoehnkeR , BurmeisterLF , KohlerJA . Adverse experience with methotrexate during 176 weeks of a long‐term prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology1990;17(12):1628‐35. FurstDE , KoehnkeR , BurmeisterLF , KohlerJ , CargillI . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. Journal of Rheumatology1989;16(3):313‐20. ">Furst 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0003" title="JiangLD , WangJY , MeiZW , NiLQ . Clinical effectiveness of methotrexate treatment in rheumatoid arthritis patients: a randomized controlled trial. Chinese Journal of Rheumatology1998;4:204‐7. ">Jiang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0005" title="SchiffMH . Leflonomide versus methotrexate: A comparison of the European and American experience. Scandinavian Journal of Rheumatology1999;28 Suppl 112:31‐5. SharpJT , StrandV , LeungH , HurleyF , Loew‐FriedrichI . Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism2000;43(3):495‐505. [PUBMED: 10728741] StrandV , CohenS , SchiffM , WeaverA , FleischmannR , CannonG , et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine1999;159(21):2542‐50. [PUBMED: 10573044] StrandV , TugwellP , BombardierC , MaetzelA , CrawfordB , DorrierC , et al. Function and health‐related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism1999;42(9):1870‐8. [PUBMED: 10513801] TugwellP , WellsG , StrandV , MaetzelA , BombardierC , CrawfordB , et al. Clinical improvement as reflected in measures of function and health‐related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve‐month, placebo‐controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 43;3:506‐14. [PUBMED: 10728742] ">Strand 1999 (ULTRA)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0006" title="WeinblattME , CoblynJS , FoxDA , FraserPA , HoldsworthDE , GlassDN , TrenthamDE . Efficacy of low‐dose methotrexate in rheumatoid arthritis. New England Journal of Medicine1985;312(13):818‐22. ">Weinblatt 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000957-bbs2-0007" title="AlarconGS , BillingsleyLM , CleggDO , HardinJG , Klippel , LuggenME , et al. Lack of association between HLA‐DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism1987;30(2):218‐20. TugwellP , BombardierC , BuchananWW , GoldsmithC , GraceE , BennettKJ , et al. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard‐item and individualized patient preference health status questionnaires. Archives of Internal Medicine1990;150(150):59‐62. WilliamsHJ , WillkensRF , SamuelsonCOJr , AlarconGS , GuttadauriaM , YarboroC , et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism1985;28(7):721‐30. ">Williams 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tender Joint Count</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tender Joint Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5+=trace</p> <p>1+=mild pain</p> <p>2+= moderate pain</p> <p>3+=severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ritchie articular index: 0=normal</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Ritchie tender joint index, with a maximum tenderness joint count of 207. Tenderness was scaled from 0=no pain to 3+ =severe pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=no pain, 1=mild pain,</p> <p>2=moderate pain,</p> <p>3=severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=none</p> <p>1=positive response on questioning</p> <p>2=spontaneous response on questioning</p> <p>3=withdrawal by patient on examination</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Swollen Joint Count</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Swollen Joint Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5+= trace</p> <p>1+= mild swelling</p> <p>2+= moderate swelling</p> <p>3+= severe swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ritchie articular index: 0=normal</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Ritchie index but not measuring hips and neck for swelling with a maximum count of 198. Swelling was scaled from 0=no swelling to 3+=severe swelling </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=no swelling, 1=mild swelling,</p> <p>2=moderate swelling,</p> <p>3=severe swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=none</p> <p>1=detectable synovial thickening with loss of bony contours</p> <p>2=loss of distinctness of bony contours</p> <p>3=bulging synovial proliferation with cystic characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Physician global assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0= no change</p> <p>1=minimal improvement</p> <p>2= moderate improvement</p> <p>3=marked improvement</p> <p>4= remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 30% improvement (scale graded from "no effect" to "significantly better")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0=asymptomatic</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1=asymptomatic</p> <p>2=mild</p> <p>3=moderate</p> <p>4=severe</p> <p>5=very severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Walking time</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 meters in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50ft walking time in seconds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mm/hr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CRP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS pain rating scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient global assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS with 0=worst and 10=normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100mm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graded from "no effect" to "significantly better". Improvement was defined by at least 1/3 increment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10cm horizontal VAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐asymptomatic</p> <p>1=mild</p> <p>2=moderate</p> <p>3=severe</p> <p>4=very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1=asymptomatic</p> <p>2=mild</p> <p>3=moderate</p> <p>4=severe</p> <p>5=very severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Work productivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty with work related activities due to health problems and health concerns on a 6‐point scale with 1=none to 6=not done, can't do it. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Morning stiffness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hand grip strength</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>kPa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Activities of daily living (ADL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient's ability to complete 18 activities of daily living on a scale of 1‐10 (maximum score=180) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HAQ disability index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 questions (8 functional categories of 2 or 3 questions) Activities performed on a daily basis </p> <p>Responses: 0=without difficulty to 3=unable to do</p> <p>Scores are summed (0‐24) and divided by the number of categories scored</p> <p>Disability index ranges from 0 to 3</p> <p>Higher scores = more disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MHAQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 questions about functional activities performed on a daily basis</p> <p>Responses: 0=without difficulty to 3=unable to do</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SF‐36 Physical component and mental component</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 scales: physical functioning, role‐physical, bodily pain, general health, vitality, social functioning, role emotional and mental health </p> <p>Higher values indicate better quality of life</p> <p>Scores are transformed to a 0‐100 scale</p> <p>Scales are combined into summary physical and mental component scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Erosion score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 joints in the hands and 12 in the feet</p> <p>The scale for erosions ranged from 0 to 5</p> <p>0 for normal joints and increasing grades for progressively more involvement<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Joint space narrowing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 joints in the hand and 12 in the feet</p> <p>Scale of 0‐4</p> <p>0=normal, 1=asymmetric or minimal narrowing &lt;11%, 2=11‐50%, 3=51‐99% and 4=complete loss of joint space and presumptive ankylosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total Sharp score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erosion + joint space narrowing scores Maximum possible total score of 422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>NR= Not reported</p> <p><sup>1"</sup>Progression from one grade to the next was scored when a discrete new erosion appeared in a previously uninvolved quadrant of the joint or carpal bone or when a preexisting erosion increased sufficiently in size to be judged greater than what could have occurred because of artifacts caused by changes in position or differences in radiation exposure or film development </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Scales used for measuring different outcomes across different studies.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/full#CD000957-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000957-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ACR 20 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.25, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ACR 50 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [1.53, 5.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 ACR 70 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.78, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Disease Remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of tender joints <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.91, ‐0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.92, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.00, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐0.88, ‐0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 &gt;50% improvement in TJC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.24 [1.07, 16.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of swollen joints <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐0.75, ‐0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.62, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.01, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐0.97, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 &gt;50% improvement in SJC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [0.80, 7.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Tender Joint Score/Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.12, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.31, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.20, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 at least 30% improvement in TJS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [1.58, 11.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [2.67, 24.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.48, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Swollen Joint Score/Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.70, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.64, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐1.01, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 at least 30% improvement in SJS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [2.40, 9.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [1.92, 13.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.73 [1.68, 13.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Physician global assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐1.51, ‐0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.74 [‐2.58, ‐0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [0.00, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐1.27, ‐0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Percent of patients improving in PhGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.93, 8.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [0.14, 161.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.18, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Walking time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.85, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.59, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.62, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 &gt;50% improvement in walking time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.33, 4.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Grip strength <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.29, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐1.06, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [‐0.44, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 ESR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.73 [‐13.91, ‐3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐10.29, 8.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐27.54, 19.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.60 [‐18.97, ‐6.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 CRP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.97 [‐41.38, 21.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.5 [‐98.02, 17.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐2.11, ‐1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000957-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Patient‐reported outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HAQ Disability Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.39, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.41, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.42, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percent of improvement in HAQ‐Di <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 at least 20% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.28, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 at least 50% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.27, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MHAQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.4 [‐0.52, ‐0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent of improvement in MHAQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.35, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &gt;or= 20% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.14, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 &gt;or= 50% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.36, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Activities of Daily Living (ADL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.0 [‐67.81, ‐32.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Activities of Daily Living (ADL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.39 [0.62, 173.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 SF‐36 Physical component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 &gt;or= 20% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.00, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 &gt;or= 50% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [1.88, 11.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 SF‐36 Mental component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 &gt;or= 20% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.79, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 &gt;or= 50% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.56, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐2.41, ‐1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐3.39, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.41 [‐3.19, ‐1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐2.37, ‐1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.65 [0.76, 41.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Patient global assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.62, ‐0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.74 [‐2.58, ‐0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐2.50, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐1.13, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Improvement in PtGA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.95, 6.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.87 [0.30, 49.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.40, 15.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Morning stiffness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.93, 8.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Morning stiffness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.87 [‐95.96, 14.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.03 [‐97.37, 43.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐61.78 [‐168.59, 45.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Work Productivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 &gt;or= 20% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.22, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 &gt;or= 50% Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.18, 4.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Patient‐reported outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000957-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Radiographic outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Radiographic Progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total Sharp Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.89 [‐13.25, 5.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Erosion Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐5.92, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Joint Space Narrowing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐8.15, 3.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 New Joint Erosions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Total patients with new erosions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 One new joint erosion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Two new joint erosions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.26, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Three new joint erosions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.07, 44.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 more than three joint erosions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.12, 2.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Radiographic outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000957-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Discontinuations</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.38, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.69, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.50, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.14, 72.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.05, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.34, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.30, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.14, 72.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.53, 5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.59, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lost to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.31, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.33, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐compliance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Protocol violation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.06, 3.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.04, 10.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Voluntary or unclear reasons <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.31, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.33, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.12, 14.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.12, 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.52, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.14, 72.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.37, 10.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.16, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hematological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.73, 16.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [0.60, 21.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 5.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.25, 21.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.12, 64.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Interstitial pneumonitis/Pulmonary infiltrates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Liver enzyme abnormalities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [1.59, 8.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.45 [1.57, 12.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.56, 12.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mucocutaneous adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.41, 6.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.41, 6.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 5.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 5.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Discontinuations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000957-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.41, 6.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.41, 6.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.36, 5.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 27 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.32, 8.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.99, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.07, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.51 [1.20, 35.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [0.93, 54.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Allergic reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.69, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.69, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Backpain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Chest pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 CNS (Nightmares, Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.26, 8.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 13.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.10, 6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Diarrhea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.33, 11.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.50, 160.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.71, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Dyspepsia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.74, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.66, 12.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.60, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Gastroenteritis/gastrointestinal distress <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.03, 4.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.77, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.72, 14.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.25, 8.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Hematological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [0.89, 13.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 96.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [0.60, 21.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.17, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.17, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.01, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.19, 18.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.99, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Liver enzymes abnormalities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Patients with elevated liver enzymes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [2.30, 9.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 ALT levels &gt;2 times ULN and &lt;or=3 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.26 [0.97, 271.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 ALT level &gt;3 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.26, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 ALT levels reversible to &lt;or=2 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.84, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 AST levels &gt;2 times ULN and &lt;or= 3 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [0.80, 15.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.6 AST levels &gt;3 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.7 AST levels reversible to &lt;or=2 times ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.50, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Mucosal ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.41, 6.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.41, 6.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Nausea and/or Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.81, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.74, 4.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.40, 8.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 New onset Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.24, 87.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.24, 87.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Psoriasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.12, 64.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.12, 64.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Pulmonary events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.08, 47.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.32, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.20, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.18, 21.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Stomatitis/oral ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.04, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.75, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.72, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000957.pub2/references#CD000957-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000957.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000957-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000957-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000957-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000957-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD000957-note-0004">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000957\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000957\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000957\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000957\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000957\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000957.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000957.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000957.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000957.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000957.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728403363"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000957.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728403371"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000957.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec3a19d879367',t:'MTc0MDcyODQwMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 